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 The ability for an organism to maintain homeostasis is of the utmost importance from the 
smallest single-celled lifeform, to the largest blue whale.  While the needs of these organisms 
may vary widely based on their environments, analogous processes are at play.  In this thesis, I 
will describe my doctoral work towards structurally and functionally understanding how a few of 
these systems, from single celled prokaryotes like streptomycetes and pseudomonads to an 
Antarctic fish, allow these organisms to survive and thrive in their respectively harsh 
environments. 
 Starting on the smallest size scale and the uptake of nutrients for use in central 
metabolism by a single-celled organism from its environment, I investigate a solute binding 
protein called HtxB from Pseudomonas stutzeri WM88.  This protein has been show to be 
involved in the uptake of reduced phosphorus compounds such as phosphite and hypophosphite 
when the more widely available phosphate is not available for utilization as a phosphorus source.  
Phosphorus, being needed for the synthesis of many biomolecules such as phospholipids, DNA, 
RNA, and ATP, can easily be the mass limiting element halting further cell division.  In this 
research, I show high resolution crystal structures of HtxB bound to hypophosphite (1.95 Å), 
phosphite (1.03 Å), and methylphosphonate (1.14 Å), while also interrogating their binding 
through microscale thermophoresis and surface plasmon resonance. 
 Moving on to the larger scale of intra-bacterial communication through signaling 
molecules, I investigate the crystal structures of ScbR2, a pseudo-gamma butyrolactone receptor, 





class of homologous proteins found throughout streptomycetes involved in the regulation of 
secondary metabolism.   
Of these homologous transcriptional repressors, three main classes are known, while all 
respond to membrane diffusible secondary metabolites.  The largest and most well studied class 
are the gamma-butyrolactone (GBL) receptors, named after the small molecule signals of which 
they bind and respond to.  To the best of my knowledge, all characterized members of this class 
repress secondary metabolism through at least one biosynthetic gene cluster, while signal is not 
present. When the threshold concentration of the cognate ligand is reached, the repressor is 
released from DNA allowing downstream genes to be transcribed. Once transcription is no 
longer repressed, the organism can produce what are usually antibiotic compounds.   
The newest class of these repressors are the butenolide receptors, also named after the 
signaling molecules they bind and respond to, which while similar, have a difference cyclized 
head group.  While only one butenolide receptor currently has an identified cognate ligand, it has 
generated significant interest as it involved in regulating avermectin production in Streptomyces 
avermitilis. A semi-synthetic analogue of avermectin, ivermectin shared the 2015 Nobel Prize for 
Physiology or Medicine.  I describe the crystal structures of AvaR1 alone, and bound to either 
avenolide or a small double stranded DNA segment.  Through various bioinformatic analyses, I 
have also been able to identify 63 sets of putative butenolide receptor and butenolide 
biosynthetic genes in various streptomycetes seen. Then I applied this information to the crystal 
structures obtained indicating a conserved butenolide ring and a more variable tail, mirroring the 
variability seen in analagous butanolide ligands. 
 The third class of homologous repressors, the pseudo gamma-butyrolactone receptors, 





sequence to that of the first discovered bona-fide GBL receptors.  Unlike the last two classes, the 
pseudo receptors are known to bind two or more, often structurally diverse secondary 
metabolites. This allows the host to integrate a variety of signals to result in the same 
downstream effect. Interestingly, these metabolites may be produced by their own colony, or 
neighboring colonies of another species. These receptors continue to differ from the first two 
classes such that they usually act to divert biosynthetic flux from the production of one 
secondary metabolite to another. Here I show the first crystal structure of a pseudo receptor, 
ScbR2. Unfortunately it is not bound to a ligand, however the lack of seven residues in the 
structure indicate the possibility of a mobile motif which presumably becomes structured upon 
ligand binding. 
Moving from the regulation of antibiotic biosynthesis, I discuss my efforts into 
understanding the function of Psf3, a stereospecific reductase that carries out the penultimate 
step of fosfomycin biosynthesis in Pseudomonas syringae.  The crystal structure of Psf3 bound 
to its cofactor and substrate, along with mutational analysis confirm the function of the enzyme’s 
role in producing this medically relevant antibiotic. 
 Lastly, I discuss the structure and function of an antifreeze-potentiating protein (AFPP) 
found in Pagothenia borchgrevinki, an Antarctic notothenioid fish endemic to the seas 
surrounding Antarctica, which often are close to -2° C.  Clearly, for an organism comprised of a 
large amount of liquid water, some mechanism is needed to avoid ice formation inside its body 
to survive.  While colligative properties are commonly known to suppress the freezing point of 
water, such high salt concentrations may hinder biological systems.  Utilizing AFPPs the 
organisms can depress the freezing point of water 300 to 500 times more than calculated through 





growth of nucleating ice crystals.  Such mechanisms are found in numerous organisms, from fish 
to insects, and have evolved independently on at least five separate occasions. Currently, four 
types of AFPPs are known in literature and classified by their structural folds.  The AFPP 
reported here, is the first member of a fifth type, having a structure reminiscent of a C1q domain. 
With the combined structural information I have obtained throughout my doctoral 
research I have increase the knowledge of how organisms, from different environments and 
kingdoms of life maintain homeostasis.  Whether these processes aid in obtaining needed 
nutrients from their environment, fending off unfriendly neighbors, or simply not being frozen 
solid, understanding these mechanisms may help future generations to more readily discover, or 
elicit the production of secondary metabolites in vitro and in vivo, and possibly even to find 















 Completing doctoral research is a long and arduous task.  Completing doctoral research 
without a strong network of people for support is presumably impossible.  Whether it be a 
positive and helpful set of lab mates, a supportive cohort of graduate students, thoughtful 
advisors and committee members, or family being there for you year after year, and teachers who 
had believed in my abilities on my path towards graduate school, or even members of 
extracurricular clubs.  These people have been instrumental for my success at the University of 
Illinois, and each plays an important role in the molding of a scientist.    
 First and foremost, I want to thank my doctoral adviser, Dr. Satish K. Nair.  From the 
beginning, he believed in me and was willing to take me into his lab.  On my first day in his 
laboratory, he asked me to find a clone a number of homologous genes into E. coli.  I had no idea 
what that entailed at the time, but he supported me along the way to grow as a person and as a 
scientist.  Satish also was nice enough to nominate me for a competitive training grant 
(Chemistry-Biology Interface Training Grant) in my second year, which upon receiving the grant 
happened to be instrumental in my ability to carry out the amount of research that I have 
completed here.  On top of freeing my time from responsibilities of being a teacher’s assistant 
for two full years, it allowed me to hone my otherwise dull public speaking abilities.  Through 
the many presentations to both peers and invited speakers through this training grant, I 
progressed immensely in terms of being a competent public speaker.  Dare I say, I have finally 
progressed to a role as a confident public speaker. 
 My thesis committee members, Dr. Erik Procko, Dr. William Metcalf, and Dr. Kai Zhang 





Erik Procko.  His positivity and advice throughout my doctoral research have been instrumental 
in my ability to carry out analysis against unsolved protein structures as he let me know about 
the ConSurf server. 
 I would like to thank all of the scientists and staff of LS-CAT, who were instrumental in 
my ability to understand and carry out both the collection of X-ray diffraction data and process 
the data into a usable state.  From helping with mundane issues such as interfaces crashing to 
determining wavelengths to collect heavy atom soaked data, this research would not have been 
possible without their help. 
 I would like to thank the large number of collaborators that I have worked with 
throughout my doctoral research as well.  From Dr. Art Devries allowing me to work on the 
antifreeze potentiating protein project, Dr. Emily Ulrich and Dr. Jonathon Chekan and their work 
on the fosfomycin project, and  Dr. Ryuichi Hirota for providing me with the E. coli codom 
optimized Ps_htxB clone.  Above all, I would like to thank Dr. Iti Kapoor for her work on the 
AvaR1 and avenolide project.  When she joined our lab, I had obtained the free AvaR1 crystal 
structure, and had just started upon the arduous task of synthesizing stereochemically pure 
avenolide with only two semesters of undergraduate organic chemistry synthesis experience.  
Even though a synthetic route had been published, it was not without fault and required many 
hours of trouble shooting and finding alterative routes around troublesome steps.  With her prior 
synthesis expertise, she was able to procure avenolide to allow us to move forward with binding 
studies and cocrystalization.  While this was the first project I starting in the Nair lab, it was also 
the last project I worked on due to the large number of complications throughout the years. 
 I would like to thank a few past teachers and professors that have guiding me along my 





bench science in me.  From being incredibly knowledgeable about chemistry topics that were 
never again touched upon throughout my next degrees, to being a strong and positive role model 
who did not quash any topic of inquire, he will always be a teacher that sticks out in my mind as 
directly responsible for corresponding educational path. 
 When I was completing my bachelor’s degree at Michigan Technological University, the 
most influential professor of min was Dr. Pushpalatha Murthy.  She taught the single most 
entertaining lab I have ever taken along with her graduate students Dr. Mimi Yang and Dr. Sasha 
Teymorian.  During this lab, I was able to help in their research for a number of weeks followed 
by being able to be the first undergraduate research assistant in years to carry out summer 
research.  Not only was this research instrumental in my acceptance to the University of Illinois, 
I did not even know that the university existed until Dr. Murthy recommended for me to apply to 
the MCB program.   
 It is impossible to overstate the importance of a stable laboratory environment on the 
metal health of the members of a laboratory.  This is doubly important when frequent twelve- or 
twenty-four-hour trips to a national laboratory are included.  Towards this point, I would like to 
thank all of the previous Nair lab members.  This lab has often felt more to me like a family than 
a group of coworkers.  Whether it be issues in personal lives or research, these people have 
always been there for me and willing to help when I was in need.     
 When mentioning the mental health of a graduate student, it is imperative to find a focus 
outside of the laboratory to lean on when research is going less than smoothly.  For me, I found 
this solace in disc golf.  I would like to thank the Champaign County Disc Golf Club to help me 
blow off steam and allow me to take my mind off research as is occasionally needed and grow 





 Of course, I would like to also thank my family for their support.  Even though it was 
hard to understand exactly what it was that I did in graduate school, and how the process as a 
whole works do to its open-ended characteristic.  You were understanding in my remote shooting 
of protein crystals at the kitchen table on holidays, and even writing my thesis during our family 
thanksgiving party this past year.  I thank you most for not asking me when it was that I was 
going to graduate every time we talked, as this is generally a graduate student’s most hated 
question. 
 Last, but not least, I would like to thank Dr. Anna SantaMaria for moral support in my 
last year of graduate school.  While it took 5 years to find each other in the chaos of graduate 
school, it made it all worth it.  I am forever grateful for you pushing me to complete my thesis 
through marathon streaming sessions of The Great British Baking Show. 
 No one is successful in a vacuum.  This is doubly so when attempting to complete 
graduate school.  If it were not apparent before coming to UIUC, graduate school makes this fact 
impossible to oversee.  My successful completion of doctoral research is largely attributed to the 
people listed below, and to them I am forever grateful.  The many lessons that I have learned 
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CHAPTER 1: STRUCTURAL CHARACTERIZATION OF 
Psf3, A PSEUDOMONAD  STEREOSPECIFIC 




Fosfomycin is a clinically approved broad-spectrum natural product antibiotic used for the 
treatment of a variety of infections, including cystitis.1 The compound contains two notable 
chemical groups, namely, a phosphonate that likely facilitates entry into target cells via the α-
glycerophosphate transporter and an epoxide that acts as a chemical warhead for inactivation of 
the target UDP N-acetylglucosamine-3-enolpyruvyltransferase that catalyzes the committed step 
in bacterial peptidoglycan biosynthesis.2,3,4,5 Because of the unique mode of action, it is often 
administered in combination with other antimicrobial agents, most notably in combination 
therapy against lung infections in cystic fibrosis patients.6 The antibacterial spectrum of 
fosfomycin includes several enteric Gram-negative bacteria, but the compound is also effective 
against several Gram-positive drug-resistant cocci, including methicillin-resistant staphylococci 
and vancomycin- resistant enterococci.7,8  
Seto and colleagues identified a putative gene cluster encoding the fosfomycin biosynthetic 
operon from Streptomyces wedmorensis NP-7 and verified the integrity of the pathway through 
heterologous expression.9 Subsequently, gene disruption analysis of the biosynthetic cluster from 
Streptomyces fradiae identified a minimal cluster containing five enzymatic activities.10  As in 
the biosynthesis of other phosphonate natural products, products, the first step of this pathway  
This chapter have been adapted from:  Olivares P, Ulrich EC, Chekan JR, van der Donk WA, & Nair SK 





consists of the thermodynamically unfavorable conversion of phosphoenolpyruvate (PEP) to 
phosphonopyruvate (PnPy) by PEP mutase.11,12 Catalysis of the irreversible decarboxylation of 
PnPy by a thiamine-dependent decarboxylase drives the reaction forward to yield 
phosphonoacetaldehyde (PnAA).Reduction of PnAA to hydroxyethylphosphonate,13,14 followed 
by methylation, in an S-adenosylmethionine (SAM)- and methylcobalamin (MeCbl)-dependent 
step yields (S)-2-hydroxypropyl- phosphonate [(S)-2-HPP].10,15,16,17,18  Epoxidation of (S)-2-HPP, 
performed by the mononuclear, non-heme Fe(II)-dependent enzyme HppE, completes the 
biotransformation to produce fosfomycin.19,20,21 
Investigations into the novel mechanism utilized for the SAM- and MeCbl-dependent 
methylation were hampered by the poor aqueous solubility of heterologously expressed Fom3, 
the enzyme that is proposed to catalyze this step.15 Attempts to identify homologous enzymes 
with more suitable solution properties focused on pseudomonads, such as Pseudomonas 
viridiflava PK-5, Pseudomonas fluorescens PK-52,22 and Pseudomonas syringae PB-5123,23 
which had been reported to be producers of fosfomycin and various analogues. Genomic 
sequencing of P. syringae PB-5123 identified a putative phosphonate biosynthetic cluster that 
encodes a characteristic PEP mutase (called Psf1) involved in C−P bond formation (Figure 
1.1A).24 While this cluster also contains a putative HppE (termed Psf4), genes homologous to 
enzymes that catalyze any of the other biosynthetic steps in Streptomyces are absent. Rather, 
some of the genes in the P. syringae PB-5123 cluster show similarity to genes present in the 
biosynthetic pathways of other phosphonates, such as FR-900098,25 and phosphinothricin.25,26 
For example, the P. syringae PB-5123 pathway lacks the ubiquitous PnPy decarboxylase that is 





unfavorable equilibrium for PnPy formation is driven forward by the addition of an acetyl group 
from acetyl-CoA by a citrate synthase-like enzyme Psf2 (Figure 1.1A).24 
While in vitro reconstitution of the remaining enzymes in the pathway was not demonstrated, a 
chemically plausible pathway for fosfomycin biosynthesis, starting from 
phosphonomethylmalate (Pmm, the product of the Psf2-catalyzed reaction), could be envisaged 
(Figure 1.1A).24 As in the Streptomyces pathway, the terminal reaction in the P. syringae PB-
5123 cluster is the epoxidation of (S)-2-HPP to yield fosfomycin.21,27 While P. syringae Psf4 is 
only distantly related to the S. wedmorensis enzyme HppE, prior studies have confirmed 
identical epoxidase activity of Psf4.27,28 However, detailed analyses of the similarities and 
differences between Psf4 and the structurally well-characterized HppE20 have yet to be 
conducted. The pseudomonad pathway harbors two genes, psf3 and psf6, whose products show 
similarities to dehydrogenases, suggesting that a likely substrate for the penultimate step may be 
2-oxopropylphosphonate (2-OPP). However, enzymatic activity for neither Psf3 nor Psf6 has 
been demonstrated. In addition, reduction of 2-OPP to 2-HPP must occur to provide the correct S 
stereochemistry, as only this enantiomer can form the product fosfomycin. Both Psf4 and HppE 
can also utilize the other stereoisomer, (R)-2-HPP, as a substrate by performing an oxidation to 








Fig. 1.1 (A) Convergent biosynthetic pathways for the production of fosfomycin as found in 
different genera. For the pathway in pseudomonads (top), the reactions that have been confirmed 
by experimental data are shown as single transformations. For the pathway from streptomycetes 
(bottom), only the methyl transfer step has not been definitively confirmed and is shown with 
dashed lines. For the pathway in Pseudomonas, the epoxide oxygen in fosfomycin is 
hypothesized to originate from the β-carbonyl of PnPy (colored red). This has been confirmed 
for the pathway in Streptomyces.16 (B and C) Reactions catalyzed by the orthologous enzymes 
Psf4 and HppE on different enantiomers of 2-HPP. The reactions are drawn using oxygen and an 
electron source as performed initially,21 but recent studies show that the reactions can also 







































































































To discern the molecular basis for this stereospecific transformation, we determined the 2.05 
Å resolution crystal structure of Psf3 with a bound cofactor and 2-OPP substrate. The roles of 
several active site residues in catalysis were established through kinetic analysis of site- directed 
variants. These biochemical studies provide mechanistic insights into the final steps in the 
biosynthesis of fosfomycin in pseudomonads and reveal new information regarding the middle 
reactions of the biosynthetic pathway that are unaccounted for in this convergent method of 
fosfomycin production. 
 
1.2 Results and Discussions 
 
Reconstitution and Stereospecificity of Psf3 Reductase Activity  
On the basis of the in vitro characterization of the acetyltransferase Psf2, we had 
previously proposed a chemical route for the formation of fosfomycin starting with Pmm. 
Although we could not establish activity for any of the enzymes in these steps, the known 
substrate for Psf4, (S)-2- HPP, was presumed to have derived from the reduction of 2-OPP. To 
ascertain the enzyme involved in this step, we expressed and purified the candidate gene product 
Psf3, which had a sequence similar to those of oxidoreductases. The substrate 2-OPP was 
produced through chemical deprotection of the commercially available dimethyl-2-OPP, and the 
integrity of the compound was established by 1H and 31P nuclear magnetic resonance (NMR) 
spectroscopy. Psf3 performed the reduction of 2-OPP to (S)-2-HPP (Figure 1.2A and Figure 
S1A). To determine the preferred hydride donor for the reduction, initial rates were determined 
using either NADH or NADPH, showing a 50-fold faster rate with NADPH as the cofactor 





consumption of NADPH, showed that Psf3 catalyzed reduction with a catalytic efficiency 
(kcat/KM) of 1.2 × 104 M−1 s−1 (Table 1.6), which is a value comparable to that of other 
reductases.33  




To establish the stereospecificity of the transformation, we examined the reverse reaction, 
i.e., the oxidation of the two enantiomers of 2-HPP by obsPsf3 in the presence of excess NADP+ 
(Figure 1.2B). Spectroscopic analysis of each reaction using 31P NMR spectroscopy showed that 
the reaction with (S)-2-HPP resulted in a new peak that is consistent with 2-OPP (as determined 
by spiking with authentic standards), while no reaction could be observed with (R)-2-HPP. These 
data establish that Psf3 catalyzes the NADPH-dependent reduction of 2-OPP, with (S)-2-HPP 
being the product. 
 
Trial kobs (s-1) 
NADPH 3.24 ± 0.02 






Fig. 1.2 (A) Michaelis−Menten curve for the wild-type Psf3 reaction using 2-OPP as a substrate. 
Error bars represent the standard deviations calculated from measurements taken in triplicate. (B) 
31P NMR spectroscopic analysis of the reverse (oxidation) activity of Psf3 using the two 
enantiomers of 2-HPP. Reactions using (S)-2-HPP resulted in a new peak that is consistent with 
2-OPP (as determined by spiking with authentic standards), while no new product could be 










Crystal Structure of Psf3 and the Basis for the Stereospecificity of Hydride Transfer  
Although bioinformatics analysis identifies Psf3 as an NAD(P)H-dependent dehydrogenase, 
attempts at structure-based modeling are precluded by the low (around 23%) level of sequence 
identity with similar proteins of known structure. Thus, we determined the 2.05 Å resolution 
cocrystal structure of Psf3 with bound ligands NADP+ and 2-OPP. The use of the oxidized form 
of the cofactor prohibited catalytic turnover of 2-OPP and facilitated determination of the 
structure of the ternary complex. The overall structure is similar to that of other enzymes within 
the 3-hydroxyacid dehydrogenase fold family and consists of an N- terminal Rossmann fold, 
composed of residues Ala3−Glu165, appended to a helical C-terminal dimerization domain 
formed by Gly167−His288 (Figure 1.3A). As in other enzymes within this fold family, Psf3 
forms homodimers, both in solution and in the crystal. Dimer formation occurs entirely via the 
C- terminal helical domain wherein two large α-helices from each monomer engage each other to 
form a central coiled coil around which four smaller helices from the respective monomers are 
stacked. The resultant dimer interface is extensive and results in the burial of roughly 1900 Å2 of 
surface area, as determined using Chimera.34  
A DALI35 search against the Protein Data Bank36 (PDB) identifies members of the 3-
hydroxyacid dehydrogenase family as the closest structural homologues, despite only modest 
conservation of primary sequence (Figure 1.4). Examples include 6-phosphogluconate 
dehydrogenase [PDB entry 3PEF; 26% sequence identity; Z score of 36.3; root-mean-square 
deviation (RMSD) of 1.9 Å over 285 aligned Cα atoms],37 tartronate semialdehyde reductase 
(PDB entry 1VPD; 21% sequence identity; Z score of 35.5; RMSD of 1.9 Å over 285 aligned Cα 
atoms),38 and L-serine dehydrogenase (PDB entry 3OBB; 26% sequence identity; Z score of 





in spite of a low sequence identity. However, unlike canonical 3-hydroxyacid dehydrogenase 
enzymes, the substrate for Psf3 is not an acid but rather a phosphonate, illustrating how a 
prevalent protein fold has been adapted to function on a divergent type of substrate.40  
The NADPH cofactor is housed within the N-terminal Rossmann fold domain, where the 
adenine ring is stabilized through stacking between Arg33 and helix α4 formed by Ser69−Ala78. 
The 2′-phosphate of NADPH is engaged by interactions with Arg33 and Lys37 (Figure 1.3B). In 
the structure of the NADH-dependent tartronate semialdehyde reductase (PDB entry 1VPD), an 
equivalent Arg33 protrudes into the active site and would occlude binding of the 2′-phosphate 
from an NADPH cofactor,38 illustrating that this residue is not predictive of NADP(H) use. The 
nicotinamide is bound on one side by the side chain of Met13, which precludes binding of the 
substrate to this face. The substrate 2-OPP is bound directly above the cofactor and is located in 






Fig. 1.3 (A) Overall structure of the Psf3 homodimer showing the orientation of the Rossmann 
fold (cyan and black) and dimerization domains (green). The second monomer is colored gray. 
The locations of bound ligands NADP+ (yellow) and 2-OPP (purple) are shown, and Arg212 that 
is involved in crossover interactions between the two monomers is also shown as brown sticks. 
(B) Simulated annealing difference Fourier maps (Fo − Fc) of Psf3 complexes contoured to 2.5σ 
(blue) showing the bound NADP+ and (C) that of 2-OPP. The coordinates for the ligand were 
omitted prior to map calculations. The final refined coordinates of the complexes are 
superimposed with important active site residues and ligands shown as sticks. Hydrogen bond 







Two main active site features specific to Psf3 likely contribute to the utilization of a 
phosphonate, rather than a carboxylate, substrate. First, the Psf3 active site is composite, and 
both monomers of the homodimer contribute residues that can engage the phosphonate substrate. 
For example, Glu180 and Tyr217 from one monomer are both poised to interact with the 
phosphonate oxygens (Figure 1.3C), whereas Arg212 (located in a loop following helix α10) 
from the other monomer caps the base of the binding site to provide additional interactions with 
a phosphonate oxygen. The R212K mutation in Psf3 results in a 103-fold decrease in catalytic 
efficiency (Table 1.6 and Figure 1.6). Second, helix α11, located in the dimerization domain, is 
shifted into the substrate-binding site relative to its position in canonical 3-hydroxyacid 
dehydrogenases, and this movement positions Tyr217 at a suitable location to interact with one 
of the oxygen atoms of the phosphonate substrate (Figure 1.3C).  
In other enzymes of this family, the equivalent residue is a small aliphatic Ala/Val or is 
otherwise positioned away from the active site. Similar composite active sites have been 
observed in the structures of other phosphonate biosynthetic enzymes such as 2-
hydroxyethylphosphonate dioxygenase41 and HppE.20  
In the Psf3 ternary complex structure, the methylketone of 2-OPP is positioned directly 
above the nicotinamide ring of the cofactor, where it would be suitably poised for hydride 
transfer (Figure 1.3B). The C3 methyl group of 2-OPP is positioned into a small hydrophobic 
pocket formed by Val234, Val238, and the methylene carbons of Arg239. Accommodation of the 
C3 methyl into this pocket is achieved by the presence of Val234 in place of the larger Phe 
residue that is located at this equivalent position in most other 3-hydroxyacid dehydrogenases 
(Figure 1.4).33 A number of residues surrounding the carbonyl oxygen may participate in a 





residues were made to investigate their involvement in Psf3 activity. The keto oxygen is 
positioned 2.4 Å from Lys173, which may help to polarize the carbonyl for favorable conversion 
into the alcohol and/or could serve as a proton donor to the alkoxide. This Lys is conserved in 
other 3- hydroxyacid dehydrogenases (Figure 1.4).33,42 Accordingly, the K173A variant does not 
demonstrate any discernible activity (Table 1.6 and Figure 1.6A). Other residues that are near the 
oxygen include Thr98 and Asn177, and the Ala variants at each of these residues demonstrate a 
103-fold loss of catalytic efficiency; neither of these variants could be saturated in substrate, 
precluding the determination of kcat or KM (Table 1.6 and Figures 1.5, 1.6B, and 1.6C). Lastly, 
although Asp242 is nearly 4.6 Å from the carbonyl oxygen, a static bridging water molecule can 
be observed in all four independent copies of Psf3 in the crystal structure (Figure 1.3C). This 
water molecule may be another candidate for donating a proton to the alkoxide during catalysis. 
The D242A mutation results in a 100-fold decrease in kcat, further affirming a role of this residue 
in catalysis (Figures 1.5E and 1.6D and Table 1.6). These various interactions observed in the 
structure provide a rationale for the stereospecificity of the hydride transfer. Binding of the 
cofactor and substrate results in the orientation of the Re face of 2-OPP above C4 of the 
nicotinamide at a distance of 2.6−2.7 Å. The numerous residues that are within interaction 
distance of the carbonyl oxygen and the hydrophobic pocket that houses the C3 atom of the 
substrate fix the orientation of 2-OPP, resulting in the formation of only the S stereoisomer 
following reduction. In the Psf3 oxidative reaction, the X-ray structure shows that the hydride is 
added to the Si face of the nicotinamide from C2 of (S)-2-HPP. For the corresponding reductive 






Fig. 1.4 Structure-based multiple-sequence alignment of Psf3 with other members of the 3-
hydroxyacid dehydrogenase family. Secondary structural elements are shown above the 
alignment. Residues in Psf3 that interact with NADP+ are indicated with a blue triangle, and 




















1.3 Materials and Methods 
 
Reagents and Materials  
Restriction enzymes (NdeI, XhoI, HindIII, DpnI), Phusion® HF polymerase, and the 
GibsonAssembly® kit were purchased from New England Biolabs. Fail Safe polymerase and 
buffers were purchased from Epicentre. QIAquick PCR Purification kit and QIAprep Spin 
Miniprep kit were purchased from Qiagen. Ampicillin (100 µg/mL) was purchased from Fisher 
and GoldBio, chloramphenicol (12.5 µg/mL) was purchased from Sigma Aldrich, and isopropyl-
β-D- thiogalactopyranoside (IPTG) was purchased from IBI Scientific. Protein purification 
buffer components were purchased from Sigma Aldrich and Fisher Scientific. Lysozyme from 
chicken egg white and DNase were purchased from Sigma Aldrich, Ni-NTA resin was purchased 
from Qiagen, and PD10 desalting columns were purchased from GE Healthcare. (2S)- and (2R)- 
hydroxypropylphosphonate were prepared as previously described.1 Dimethyl 2- 
oxopropylphosphonate, NAD(P)H, NADP+, iron ammonium sulfate, hydrogen peroxide, 
catalase from bovine liver, Chelex 100 sodium, and fosfomycin were purchased from Sigma 
Aldrich. L- ascorbic acid was purchased from Acros Organics. D2O was purchased from 
Cambridge Isotope Labs. 96-2 Shallow Well screening trays were purchased from Art Robbins 
Instruments. VDX48 Plates used for optimization of crystal conditions, and the Index screening 
system were purchased from Hampton Research. 
Synthesis of 2-oxopropylphosphonate (Carried out by Emily Ulrich)  
Dimethyl 2-oxopropylphosphonate (1 g, 6 mmol, 1 equiv.) was dissolved in 16 mL of dry 





temperature. The solvent was removed under reduced pressure. The material was taken up in 16 
mL of EtOH/H2O and stirred for 15 min. The solvent and volatiles were removed via rotary 
evaporation to afford the product (97% yield). The NMR spectral data of the product agree with 
those previously reported. 
Instruments  
31P NMR experiments were performed on an Agilent 600 MHz spectrometer equipped 
with an OneNMR probe. Spectra were recorded at room temperature in 20% D2O and referenced 
to 85% phosphoric acid. Samples were spiked with authentic standards to confirm peak 
identities. UV- visible spectroscopy experiments were performed on a Varian Cary 4000 
spectrophotometer. Anaerobic experiments were performed in a Coy Laboratory Products 
anaerobic chamber maintained with an atmosphere of 97%/3% N2/H2. 
Cloning, expression, and purification of Psf3 and Psf3 mutants (Cloning carried out by 
Emily Ulrich, Site-directed mutations generated by Philip Olivares) 
Genes were amplified from the genomic DNA of Pseudomonas syringae PB-5123 with 
appropriate ends for combination with pET-15b expression vectors via Gibson assembly2 with 
either Psf3 F and Psf3 B (Table 1.4). Briefly, genomic DNA from P. syringae PB-5123 was 
prepared from an overnight culture (LB, 30 ºC) using the UltraClean® Microbial DNA Isolation 
Kit (Mo Bio Laboratories, Inc.) and following the manufacturer’s instructions. The PCR samples 
(50 µL) to amplify psf3 contained 1X Fail Safe buffer G, 0.5 µM of each primer, 130 ng gDNA, 
and 0.02 U/µL Phusion® HF polymerase. The samples were run through the following program 
on a BioRad thermocycler: 98 ºC 30 s, 30 cycles of 98 ºC 10 s, 55 ºC 30 s, 72 ºC 1 min, then 72 





PCR Purification Kit) were used for Gibson assembly with linear pET-15b vector (with a 2:1 
insert:vector ratio, see below for linear pET-15b preparation). The ligation reaction (20 µL) 
contained 1X NEB Gibson master mix and was incubated at 50 ºC for 1 h. An aliquot (2 µL) was 
used to transform Escherichia coli DH5α electrocompetent cells. The cells recovered in LB for 1 
h at 37 ºC and were plated onto LB/amp100 for growth at 37 ºC overnight. Colonies were picked 
for plasmid preparation (QIAprep Spin Miniprep Kit) and sequences were confirmed by ACGT, 
Inc. Linear pET-15b was prepared by digesting the circular plasmid with NdeI and PCR 
amplifying the resulting product. The PCR sample (50 µL) contained 1X Fail Safe buffer G, 50 
µM of each primer, 20-40 ng of linear plasmid, and 0.03 U/µL Fail Safe polymerase. The sample 
was run through the following program: 98 ºC 3 min, 30 cycles of 98 ºC 10 s, 60 ºC 1 min, 72 ºC 
5 min, then 72 ºC 8 min. The product was treated with DpnI and purified using the QIAquick 
PCR Purification Kit. 
The mutants of Psf3 were created through QuikChange mutagenesis43 following a 
previously described method modified to include a “Hot Start” in which Phusion® HF 
polymerase was added to the reaction mixture during the initial denaturing step. DNA oligomers 
utilized in the creation of Psf3 mutants are listed in Table 1.4. After mutagenesis, QuikChange 
products were treated with DpnI (New England BioLabs) and used for transformation of 
chemically competent E. coli DH5α cells. Correct mutants were confirmed by sequencing 
(ACGT Inc.). 
Protein Expression and Purification For Use In in vitro Assays (Carried out by Emily 
Ulrich) 
E. coli Rosetta 2 (DE3) pLysS cells (Novagen) harboring the designated plasmid were 





shaking at 37 ºC until an optical density at 600 nm of 0.6-0.8 was reached. The culture flasks 
were then placed in ice water for 10 min before induction with IPTG (0.1 mM final 
concentration). After incubation for 10-12 h at 18 ºC while shaking, the cells were harvested by 
centrifugation, and the pellet was washed with phosphate-buffered saline buffer, pH 7.4. The 
cells were resuspended in lysis buffer (Psf3 and variants: 50 mM HEPES pH 7.5, 200 mM KCl, 
20 mM imidazole, 10% glycerol), treated with 1000 U DNase/30 mL of buffer (cells harboring 
Psf3 and variants were also treated with 1 mg/mL lysozyme), and incubated for 30 min at 4 ºC. 
Cell lysis was performed by two passages through a chilled French pressure cell (Thermo 
Electron Corporation) and the cell debris was removed by centrifugation (35,000 × g for 1 h at 4 
ºC). The remainder of the purification procedure was performed at 4 ºC. The supernatant was 
first incubated with equilibrated Ni-NTA resin (2.5 mL resin per L overexpression culture) for 
30 min and the flow- through was collected. The resin was washed twice with 10 column 
volumes of wash buffer (Psf3and variants: 50 mM HEPES pH 7.5, 200 mM KCl, 50 mM 
imidazole, 10% glycerol) and the protein was eluted off the resin with elution buffer (Psf3 and 
variants: 50 mM HEPES pH 7.5, 200 mM KCl, 250 mM imidazole, 10% glycerol). Fractions 
were pooled based on measurement of absorbance at 280 nm on a NanoDrop spectrophotometer 
(Thermo Scientific), and the pooled fractions were concentrated to ~2 mL using an Amicon Ultra 
centrifugal filter with a 10 kDa molecular weight cut off. The concentrated fractions were 
desalted using a PD10 column equilibrated with storage buffer (Psf3 and variants: 50 mM 
HEPES pH 7.5, 200 mM KCl, 10% glycerol), and the final product was aliquoted and stored at -
80 ºC. Purity was assessed by SDS-PAGE and the final concentration was measured by 





coefficient(M-1 cm-1) used for each protein was: 22,920 for Psf3 and variants (calculated using 
the SIB ExPASy Bioinformatics Resources Portal, http://www.expasy.org).4 
Protein purification for Crystallographic Studies  
Wild type protein was grown in an identical manner for crystallization as with protein 
intended for use in in vitro assays, while preparation of the selenomethionine (SeMet) labeled 
proteins was carried out by the repression of methionine synthesis in defined media.44 Cells were 
pelleted at 3566 x g before resuspension with 500 mM NaCl, 10% glycerol, and 20 mM Tris pH 
8.0 for lysis. A 6 °C chilled cell homogenizer (Avestin) was utilized for cell lysis using 4 passes 
at 7,000 psi. Soluble protein was then separated from the insoluble fraction for 1 h at 15,400 x g 
at 4 °C. The protein was loaded onto a HisTrap HP column (GE Healthcare) and washed with 50 
mL of 1 M NaCl, 20 mM Tris pH 8.0, 30 mM imidazole. A 40 mL gradient elution was 
performed over 20 min starting from the aforementioned wash buffer to 1 M NaCl, 20 mM Tris 
pH 8.0, 250 mM imidazole. Hexahistidine tag cleavage was performed with thrombin protease 
for 12 h in the case of Psf3 variants. Removal of the affinity tag was followed by size exclusion 
chromatography using an ÄKTApurifier with attached Superdex HiloadTM 75 16/60column (GE 
Healthcare) and a flowrate of 1 mL min-1 of running buffer. Size exclusion chromatography 
buffer for Psf3 variants consisted of 300 mM KCl, 20 mM HEPES pH 7.5. Protein was 
concentrated, when needed using Amicon® Ultra Centrifugal Filters. 
Determination of the Psf3  X-ray crystal structures  
Polymeric protein was concentrated following size exclusion chromatography with 
centrifugal filters (10 kDa MWCO) and incubated with the appropriate ligands prior to 





use of commercially available sparse matrix crystallization screens using 0.4 µL sitting drops 
comprised of an equal volume of protein and well condition. All optimization of initial crystal 
conditions were carried out using hanging drop vapor diffusion with 1 µL well condition and 1 
µL protein and ligand solution. When noted, cryoprotective solutions were used before 
vitrification of protein crystals prior to data collection. These cryoprotective solutions were 
modified mother liquor solutions supplemented with a denoted concentration of cryoprotectant. 
All X-ray diffraction data were collected at the Life Sciences Collaborative Access Team 
(Sector-21) Argonne National Lab (Lemont, IL). 
The Psf3, NADP+, and 2-OPP cocrystals were obtained by optimization of the initial 
condition (Index 58) to 43% v/v polypropylene glycol P400, and 0.1 M Bis-Tris Methane pH 6.5 
at 4 °C using a protein concentration of 12 mg/mL with 2 mM NADP+, and 2 mM 2-OPP. 
Preparation of the selenomethionine (SeMet) labeled protein was carried out by the 
repression of methionine synthesis in defined media,5 while its purification was identical to that 
of the native counterpart. The SeMet-Psf3 crystal was obtained from drops containing 39% v/v 
polypropylene glycol P400, 0.1 M Bis-Tris methane pH 6.5, 2 mM dithiothreitol, and 5 mg/mL 
Psf3 with 2 mM NADP+, 2 mM 2-OPP.  
For structure determination of Psf3, a 15-fold redundant data set was collected from 
crystals of SeMet labeled crystals at a wavelength of 0.97856 Å to a limit of 2.35 Å resolution. 
Data were integrated and scaled using XDS.45 The heavy atom substructure was determined 
using HySS as implemented in the PHENIX46 suite of programs. A total of 14 selenium sites 
were refined to yield a figure of merit of 0.298. Phase improvement using solvent flattening and 
non-crystallographicsymmetry averaging yielded a map into which the entire protein backbone, 




























Table 1.2: Psf3 Crystallographic Refinement Parameters  
 Native 2-OPP NADP+ SeMet 2-OPP NADP+ 
Data collection   
Space Group P21 P212121 
Cell: a, b, c (Å) 46.0, 87.4, 164.1 46.1, 87.5, 153.4 
α, β, γ (o) 90.0, 92.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å)1 50.0-2.05 (2.09-2.05) 50.0-2.30 (2.34-2.3) 
Total reflections 278,038 142,031 
Unique reflections 78,862 28,055 
Rsym (%) 12.4 (58.1) 10.2 (47.2) 
I/σ(I) 9.6 (2.0) 13.9 (2.4) 
Completeness (%) 96.6(96.6) 98.6 (87.4) 
Redundancy 3.5(3.6) 5.1 (3.7) 
Refinement   
Resolution (Å) 25.0-2.05   
No. reflections 73,331  
Rwork / Rfree2 17.0/20.7  
Number of atoms   
Protein 8481  
Ligand 192/32  
Water 885  
B-factors   
Protein 27.2  
Ligand 22.6/25.0  
Water 34.9  
R.m.s deviations   
Bond lengths (Å) 0.008  
Bond angles () 0.957  
Ramachandran Plot   
Residues in favored region 939 (95.7%)  
Residues in allowed region 38 (3.9%)  
Residues in outlier region 4 (0.4%)  
Residues modeled 3-288  
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 





Organisms, Media, and Reagents 
All oligonucleotides used in this study were purchased from Integrated DNA 
Technologies (Table 1.4). Reagents used for molecular biology experiments and Luria- Bertani 
(LB) medium were purchased from New England BioLabs, Thermo Fisher Scientific, or Gold 
Biotechnology. Plasmid sequencing was performed by ACGT Inc. unless otherwise noted. 
Escherichia coli strain DH5α was used for plasmid maintenance, and E. coli Rosetta 2 DE3 
pLysS was used for protein overexpression. P. syringae PB-5123 was used for the cloning and 
amplification of both psf3 . Detailed notes of organisms and plasmids used in this study are listed 
in Tables 1.3 and 1.5.  
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Table 1.5: Plasmids used in this study 
 
Name 5’ Sequence 3’ 
Psf3 F GCAGCGGCCTGGTGCCGCGCGGCAGCCATATGAACCGCGTGGTGGGGTTCAT 
CGG 
Psf3 B CCTTTCGGGCTTTGTTAGCAGCCGGATCCTCGAGTCATGACGCCTTCCATGCTT 
TGTTA 
Psf3 T98A F GTGGTTGACCTGAGCGCCATAGCCCCGGAAAC 
Psf3 T98A B GTTTCCGGGGCTATGGCGCTCAGGTCAACCAC 
Psf3 K173A F GGCGCAGCGTCTGGCAATTCTCAACAACC 
Psf3 K173A B GGTTGTTGAGAATTGCCAGACGCTGCGCC 
Psf3 N177A F GTCTGAAAATTCTCAACGCCCTGGCTGAAAGCATC 
Psf3 N177A B GATGCTTTCAGCCAGGGCGTTGAGAATTTTCAGAC 
Psf3 R212K F GATGTCTTCACGTCCTGTGCAGGGCGCTCGGCCTATATG 
Psf3 R212K B CATATAGGCCGAGCGCCCTGCACAGGACGTGAAGACATC 
Psf3 D242A F GTGCGCTGCAAGGCTCTCGAACTGGC 
Psf3 D242A B GCCAGTTCGAGAGCCTTGCAGCGCAC 
pET15-XhoI_fw CTCGAGGATCCGGCTGCTAACAAAGCCCGAAAGG 
pET15-NdeI_rc CATATGGCTGCCGCGCGGCACCAGGCCGCTG 
Name Features Source 
pET-15b AMPR Novagen 
pET-15b-psf3 AMPR (NdeI/XhoI) This study 
pET-15b-psf3 D242A AMPR (NdeI/XhoI) This study 
pET-15b-psf3 N177A AMPR (NdeI/XhoI) This study 
pET-15b-psf3 T98A AMPR (NdeI/XhoI) This study 





Determination of Psf3 Activity by 31P NMR Spectroscopy (Carried out by Emily Ulrich) 
The assay (500 μL) contained 50 mM HEPES (pH 7.5), 30 μM wild- type (WT) or 
variant Psf3, 2 mM NADPH, and 2 mM 2-OPP. The reaction mixture was incubated at room 
temperature (RT) for 13 h, and the reaction was quenched by removal of the enzyme using a 
Millipore centrifuge filter (10 kDa molecular weight cutoff, 5 min,16000g). D2O [100 μL, final 
concentration of 20% (v/v)] was added to the flow-through before sample measurement. 
Reactions were performed in duplicate. Spectra were analyzed using MestReNova version 8.0.0. 
To perform the reverse reaction, the assay components were the same except that 2 mM NADP+ 
and 1 mM (S)-2-HPP or (R)-2-HPP were substituted for NADPH and 2-OPP and 15 μM Psf3 
WT was used instead of 30 μM Psf3 WT.  
Determination of Kinetic Parameters for Wild-Type and Variant Psf3 (Carried out by 
Emily Ulrich) 
  Michaelis−Menten parameters for Psf3 with respect to 2-OPP were determined using 
reaction mixtures (200 μL) that contained 50 mM HEPES (pH 7.5), 0.25 μM Psf3 WT or 5 μM 
Psf3 variant, 250 μM NADPH, and varying amounts of 2-OPP (0.05−8 mM). Hellma Suprasil 
quartz cuvettes (path length of 1 cm) were used, and the change in absorbance at 340 nm was 
recorded. Reactions were performed in triplicate. Rates were measured using the Cary WinUV 
kinetics software version 6.0.0 1547, and data were fit to the Michaelis−Menten equation using 
Igor Pro version 6.32A. The same reaction was also performed with varying NADPH 
concentrations (200 and 350 μM) and a saturating 2-OPP concentration (4 mM). The initial rates 
recorded were the same as those with 250 μM NADPH. Hence, the assay contained saturating 





and rates were analyzed in the same way that is described above, with the reaction mixture 














Fig. 1.5  31P NMR spectroscopic analysis of the reactions of 2-OPP with (A) WT Psf3, B) Psf3-
N177A, (C) Psf3-R212K, (D) Psf3-T98A, (E) Psf3-D242A, (F) Psf3-K173A, and (G) no 
enzyme. A minor impurity of unknown structure remaining from the 2-OPP synthesis (chemical 






Fig. 1.6 Dependence of the rate of reduction of 2-oxopropylphosphonate by Psf3-R212K (A), 
Psf3-T98A (B), Psf3-N177A (C),  on substrate concentration. (D) Steady-state Michaelis-
Menten kinetics of Psf3-D242A with respect to 2- oxopropylphosphonate. Error bars represent 





Table 1.6 Steady-state Michaelis-Menten kinetic parameters of wt Psf3 and variants with 
respect to 2-OPP. 
aNot determined because the enzyme could not be saturated with substrate.  
bValue was determined using a line that was fit to pass through the origin. 
 
1.4 Concluding Remarks 
 
We describe here the in vitro activity reconstitution and crystallographic analysis of the 
penultimate enzymes involved in fosfomycin biosynthesis in pseudomonads. The fosfomycin 
biosynthetic pathways in Streptomyces and Pseudomonas are likely the products of 
convergence.24 Although biochemical reconstitution of the entire pathway has not yet been 
established, a plausible route for the production of 2-OPP has been proposed starting from 
phosphonomethylmalate,24 the last biochemically detected intermediate in this pathway. The 
reduction of 2-OPP to (S)-2-HPP by Psf3, followed by epoxidation by Psf4 to yield fosfomycin, 
completes the latter half of this pathway.  
An intriguing aspect of fosfomycin production that derives from this study relates to the 
observed tolerance of HppE and Psf4 for both stereoisomers of 2-HPP. Using an oxygen- 
dependent activation system (FMN), Liu and co-workers have shown that HppE is a competent 
catalyst utilizing either the nonphysiological substrate (R)-2-HPP (kobs of 0.58 ± 0.02 min−1) or 
Mutation Rationale Kcat (s-1) Km (mM) Kcat/ Km 
WT  4.4 ± 0.1 0.38 ± 0.03 (1.2 ± 0.1) x 104 
D242A Static water binding 0.047 ± 0.001 0.77 ± 0.07 (6.1 ± 0.6) x 101 
T98A Static water and 
ketone binding 
n.d. a n.d. a (2.6 ± 0.1) x 101 
N177A Ketone binding n.d. a n.d. a (4.8 ± 0.1) x 101 
R212K Phosphonate binding n.d. a n.d. a b(2.4 ± 0.1) x 101 
K173A Ketone binding and 
possible base 





the physiological S isomer (kobs of 0.31 ± 0.06 min−1).31 The molecular basis for the altered 
regioselectivity is explained by the structural data for HppE.30 We were able to use this “off-
pathway” reaction of Psf4 to our advantage by successfully driving the formation of 2-OPP 
through the Psf3 and Psf4 “on-pathway” transformations to make fosfomycin from racemic 2-
HPP. Ongoing studies are aimed at elucidating the full biosynthetic pathway to fosfomycin in 
pseudomonads. Understanding the convergent biosynthetic routes to fosfomycin may also 














CHAPTER 2: STRUCTURAL CHARACTERIZATION 
AND LIGAND BINDING OF HtxB, A REDUCED 




 Clearly, phosphorus is an essential element for the growth of any organism.  Phosphorus 
is not only essential in general, but for many of the most important cellular functions.  Be it for 
use in the biosynthesis of structural molecules of a cell such as phospholipids, to uses in 
generating the energy currency ATP, to generating phosphorylated proteins, cyclic AMP, and 
other similar molecules for signaling purposes, to the polyphosphate backbones of RNA and 
DNA for general protein generation and DNA duplication before cell division.50 
With the import biological roles of phosphorus, it can easily be a limiting reagent for 
growth.  Because of this, nature has come up with different ways of obtaining various 
phosphorus compounds across cell membranes into a living system.  Because phosphorus is 
usually found in negatively charged molecules such as inorganic phosphate and phosphate esters, 
they are therefore not membrane diffusable, transmembrane systems have evolved to move these 
important molecules into cells51.  These transporters may be specific for inorganic phosphate 
(transmembrane protein PitA52, and ABC transporter PstSCAB), phosphate esters (glycerol-3-
phosphate transporters major facilitator superfamily GlpT53, ABC transporter UgpABCE54, and 
sugar phosphate antiporter UhpT55), or even reduced phosphorus compounds (phosphonate ABC 
transporter PhnD56, phosphite ABC transporter PtxABC57 and hypophosphite  ABC transporter 





Once these varied phosphorus compounds are successfully imported into the cell, they 
are to be converted into compounds integrable into central metabolism, although most organisms 
do not have the ability to convert reduced phosphorus compounds such as hypophosphite, 
phosphite, and phosphonates into the more oxidized phosphate species.  In order for such a 
transformation to occur, special enzymes must be present.  In the case of phosphite, an NAD-
dependent phosphite oxidase called PtxD has been identified to carry out the conversion of 
phosphite into phosphate in Pseudomonas stutzeri WM88.58  In organisms such as P. stutzeri 
WM88 who also have the ability to import hypophosphite, a second enzyme is needed to carry 
out the oxidation of hypophosphite to phosphite.  In this case, HtxA, a hyophosphite 
dioxygenase.59  When these two enzymes are present in the cell, the reduced phosphorus can 
make its way into central metabolism. 
A major player of phosphorus import for microorganisms are ABC transporters with 
varying specificities.  These ABC transporter systems generally have nanomolar to micromolar 
affinity to their preferred solute, and in many cases the ability for these transporters to function at 
low solute concentrations is tied to the presence of a solute binding protein.60  The simple 
phosphorus compounds (phosphate, phosphite, methylphosphonate, and hypophosphite) all share 
the same geometry around the phosphorus center, as such, it is an interesting conundrum as to 
how these transporters discriminate between the structurally similar ligands.  In order to 
understand the molecular basis that determines ligand specificity of this solute binding protein, 
structural studies were carried out.  Here, I discuss the Pseudomonas stutzeri WM88 HtxB 
(Ps_HtxB) X-ray cocrystal structures (hypophosphite, phosphite, and methylphosphonate) in 
comparison to other reduced phosphorus compound solute binding proteins.  Binding parameters 





Structural feature needed for ligand discrimination are important, as the solute binding 
specificity has recently been used as a part of a novel biocontainment strategy hinging on the 
ability only to uptake hypophosphite, rather than more oxidized phosphorus compounds, 
understanding the residues important for these differences is crucial to understand what 
mutations may allow for escape.61  SBPs usually have nanomolar to micromolar affinity to their 
ligands, further necessitating the understanding of these binding interactions.62 
 
2.2 Materials and Methods 
 
Cloning 
E. coli codon optimized htxB plasmid graciously provided by Dr. Ryuichi Hirota. 
Determination of HtxB ligand dissociation constants 
Microscale Thermophoresis was performed, detailed experimental procedures are 
described below.  Binding assays were carried out in a buffer composed of 300 mM KCl, 20 mM 
HEPES pH 7.5.  Microscale thermophoresis (MST) measurements were taken using a a 
Monolith™ NT.LabelFree instrument from NanoTemper Technologies with Monolith™ 
NT.LabelFree capillaries.  All binding assays utilize label free measurement from HtxB inherent 
fluorescence. 
Assays interrogating hypophosphite binding used a range of ligands concentrations 
starting at 10 µM with a series of 15 two-fold dilutions with an end protein concentration of 50 





Assays interrogating methylphophonate binding utilized an overnight incubation between 
protein and ligand with a high ligand concentration of 50 mM followed by 15 two-fold dilutions. 
Binding analysis was initially performed with MO.Affinity Analysis v2.1.5 before data 
export into Origin 2019 for error calculations from triplicate data points. 
Organisms, Media, and Reagents  
Reagents used for molecular biology experiments and Luria-Bertani (LB) medium were 
purchased from New England BioLabs, Thermo Fisher Scientific, or Gold Biotechnology.  
Plasmid sequencing was performed by ACGT Inc. unless otherwise noted.  Escherichia coli 
strain DH5α was used for plasmid maintenance and E. coli Rosetta 2 DE3 pLysS was used for 
protein overexpression. Detailed notes of organisms and plasmids used in this study are provided 
in tables 2.1 and 2.2.  A vector containing E. coli codon optimized Pseudomonas stutzeri WM88 
htxB was provided by Dr. Ryuichi Hirota of Hiroshima University. 
Reagents and Materials 
Restriction enzymes (DpnI), and Phusion® HF polymerase, were purchased from New 
England Biolabs. Ampicillin (100 µg/mL) was purchased from Fisher and GoldBio, 
chloramphenicol (12.5 µg/mL) was purchased from Sigma Aldrich, and isopropyl-β-D-
thiogalactopyranoside (IPTG) was purchased from IBI Scientific. Protein purification buffer 
components were purchased from Sigma Aldrich and Fisher Scientific. 96-2 Shallow Well 
screening trays were purchased from Art Robbins Instruments. VDX48 Plates used for 
optimization of crystal conditions, and the Index screening system were purchased from 
Hampton Research.  Hypophosphite was obtained from Aldrich, methylphosphonic acid  was 





Monolith™ NT.LabelFree capillary tubes used during MicroScale Thermophoresis experiments 
were obtained from NanoTemper Technologies. 
Instruments 
 MicroScale Thermophoresis was performed with a Monolith™ NT.LabelFree from 
NanoTemper Technologies. 
Protein purification for Binding Assays and Crystallographic Studies  
Wild type and mutant protein was grown in an identical manner.  E. coli Rosetta 2 (DE3) 
pLysS cells (Novagen) harboring the designated plasmid were grown in LB supplemented with 
100 µg/mL ampicillin and 12.5 µg/mL chloramphenicol while shaking at 37 ºC until an optical 
density at 600 nm of 0.6-0.8 was reached. The culture flasks were then placed in an ice bath for 
15 min before induction with IPTG (0.1 mM final concentration). After incubation for 10-12 h at 
18 ºC while shaking, the cells were harvested by centrifugation at 3484 x g.  The cells were 
resuspended with 500 mM NaCl, 10% glycerol, and 20 mM Tris pH 8.0 for lysis.  Soluble 
protein was then separated from the insoluble fraction for 1 h at 15,400 x g at 4 °C. The protein 
was loaded onto a HisTrap HP column (GE Healthcare) and washed with 50 mL of 1 M NaCl, 
20 mM Tris pH 8.0, 30 mM imidazole.  A 40 mL gradient elution was performed over 20 min 
starting from the aforementioned wash buffer to 1 M NaCl, 20 mM Tris pH 8.0, 250 mM 
imidazole. Size exclusion chromatography using an ÄKTApurifier with attached Superdex 
HiloadTM 75 16/60 column (GE Healthcare) and a flowrate of 1 mL min-1 of running buffer was 
performed with purified protein to separate monomeric protein from aggregation and exchange 
buffer.  Size exclusion chromatography buffer for HtxB variants consisted of 100 mM KCl, 20 
mM HEPES pH 7.5. Protein was concentrated using 10 kDa MWCO Amicon® Ultra Centrifugal 





modified to 300 mM KCl. 
Crystallization and Determination of the HtxB X-ray crystal structures 
Protein was concentrated with a 10 kDa MWCO centrifugal filter after size exclusion 
chromatography.  At least 30 minutes before crystal trays were prepared, protein was incubated 
with the given ligand. Initial crystallization conditions were determined through the use of 
commercially available sparse matrix crystallization screens using 0.4 μL sitting drops 
comprised of an equal volume of ligand incubated protein and well condition.  Crystal condition 
optimizations were carried out using 2 μL drops and the hanging drop vapor diffusion method   
with equal volumes of well condition and protein ligand solution. These cryoprotective solutions 
were prepared as modified mother liquor solutions supplemented with a denoted concentration of 
cryoprotectant. Cryoprotective solutions were used before vitrification of protein crystals prior to 
data collection. All protein crystals used to obtain X-ray diffraction data were obtained at 9 °C, 
and all data were collected at the Life Sciences Collaborative Access Team (Sector-21) Argonne 
National Lab (Lemont, IL). The HtxB structure was phased with single wavelength anomalous 
diffraction coming from a 6 hour 10 mM triethyl lead acetate soak of a crystal formed in equal 
volumes of 23 mg/mL HtxB, 2 mM NaPO3, and 23% PEG3350, 0.1 M bis-tris methane pH5.5 
0.2 M lithium sulfate. The heavy atom substructure was determined using HySS as implemented 
in the PHENIX46 suite of programs.  Only 1 heavy atom was found, and using those coordinates, 
AutoSol was run determining that 14 heavy atoms are present in the asymmetric unit with a 
figure of merit of 0.347 while modeling 256 residues. Refinement cycles using REFMAC547 and 
manual rebuilding using COOT48 were carried out until convergence to the final models.  Ligand 






 HtxB crystals bound with methylphosphonate were obtained with equal volumes of 23 
mg/mL HtxB with 5mM methylphosphonate protein solution, and well condition comprised of 
26% polyethylene glycol 3350, 0.1 M bis-tris methane pH 5.5, 0.2 M Li2SO4 at  9 °C. 30% 
polyethylene glycol 3350 was supplemented to the final well condition as a cryoprotectant. The 
initial crystal condition of tube 2.45 from JCSG plus comprised of 0.2 M Li2SO4, 0.1 M bis-tris 
methane pH 5.5, 25% w/v polyethylene glycol 3350  
 The Phosphite bound HtxB crystals were obtained with equal volumes of protein solution 
comprised of 24 mg/mL HtxB and 2mM HNaPO3, and well condition comprised of 12% w/v 
polyethylene glycol 8000, 0.1M bis-tris methane pH 5.5, 0.2M Li2SO4, 20% v/v glycerol. 30% 
v/v glycerol was supplements to the well condition to act as a cryoprotectant.  
 Hypophosphite bound HtxB crystals were obtained through equal volumes of  23 mg/mL 
HtxB and 2mM H2PO2 as protein solution, and well condition comprised of 26% w/v 
polyethylene glycol 3350, 0.1M bis-tris methane pH 5.5, 0.2 M Li2SO4. Well condition was 
supplemented to 30% w/v polyethylene glycol 3350 as a cryoprotectant. The initial crystal 
condition of tube 2.45 from JCSG plus comprised of 0.2 M Li2SO4, 0.1 M bis-tris methane pH 











Table 2.1: Plasmids used in this study 
Name Features Source 
pET-21b AMPR Novagen 
pET-21b-OPThtxB AMPR  Dr. Ryuichi Hirota 
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Table 2.3: Crystallographic refinement parameters 
 
 HtxB-Phosphite HtxB-Hypophosphite HtxB-Methylphosphonate 
Data collection    
Space Group P212121 P212121 P212121 
Wavelength (Å) 0.978720 0.978720 0.978720 
Cell: a, b, c (Å) 51.7, 55.6, 98.4 51.798, 55.684, 98.648 51.835, 55.561, 98.216 
α, β, γ (o) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å)1 48.46-1.03 49.43-1.95 45.88-1.14 
Total reflections 1,502,922 (112,403) 302,356 (30,930) 1,254,223 (55,239) 
Unique reflections 139,728 (13,627) 20,919 (2,100) 97,140 (7,944) 
Rsym (%) 9.98 (8.2) 17.7 (13.9) 7.1 (6.8) 
I/σ(I) 13.89 (2.55) 14.05 (2.23) 17.93 (2.24) 
Completeness (%) 99.68 (98.51) 97.48 (100.00) 94.14 (77.88) 
Redundancy 10.8 (8.2) 14.5 (14.7) 12.9 (7.0) 
Refinement    
Resolution (Å) 
35.33  - 1.031 
(1.067  - 1.031) 
48.49  - 1.95 
(2.02  - 1.95) 
37.9  - 1.143 
(1.184  - 1.143) 
No. reflections 139,726 20,914 97,137 
Rwork / Rfree2 17.6/18.5 18.3/21.8 18.6/27.9 
Number of atoms    
Protein 2,197 2,105 2,228 
Ligand 4 3 5 
Water 401 215 347 
B-factors    
Protein 11.31 25.72 13.56 
Ligand 6.74 17.77 8.55 
Water 23.12 35.10 24.66 
R.m.s deviations    
Bond lengths (Å) 0.018 0.015 0.021 
Bond angles () 2.45 1.96 2.37 
Ramachandran Plot    
Favored, outliers (%) 97.34, 0.0 96.95, 0.76 95.83, 0.76 
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 





2.3 Results and Discussions 
Solute binding proteins (SBPs) are a heavily structurally studied group of bacterial 
proteins with over 500 structures deposited into the PDB.36   Pseudamonas stutzeri WM88 HtxB, 
called simply HtxB from now on, is structurally characterized as a Class II, cluster D-IIIa solute 
binding protein according to Poolman’s updated structural SBP classification scheme.63  These 
SBPs are parts of type I ABC transporters with ligands such as phosphate, tungstate, and 
molybdate.   
Like other members of this protein class, HtxB consists of two globular domains fused by 
two flexible loops near the ligand binding pocket and center of mass of the molecule.  Domain 1 
consists of the first 127 residues, before the peptide chain crosses into the Domain 2.  This 
domain holds residues 128 to 236 before the peptide chain crosses back to finish the structural 
domain 1 with residues 237 to residue 300 shown in Fig 2.1. Between the two domains, a hinge 
regions consists around the residues of P127, F128, Y129, K130, and S233, K234, L235, and 
P136.  These eight residues run in an antiparallel fashion between the two globular domains. 
In order to investigate the ligand binding specificity of HtxB, binding studies were 
carried out along with the determination of cocrystal structures with hypophosphite, phosphite, 
or methylphosphonate bound.  These data illustrate a structural basis underlying the ligand 






Fig. 2.1 (A) Hypophosphite bound HtxB,  (B) phosphite Bound HtxB, and (C) 






Looking at hypophosphite, fewer hydrogen bonds are able to form in comparison to more 
oxidized phosphorus compounds such as phosphite and phosphate.  Surprisingly,  In the 1.95 Å 
resolution structure, one of the two oxygen atoms of this ligand is involved in making three 
hydrogen bonding contacts, while the adjacent oxygen is involved in making four of these 
contacts.  The  O1 oxygen atom makes contacts to the sidechain oxygen of Y129 (2.59 Å), the 
sidechain oxygen of S162 (2.81 Å), the backbone nitrogen of S162 (2.75 Å), and the nitrogen of 
the sidechain amide of N160 (3.10Å).  The O2 oxygen of hypophosphite is bound to both the 
backbone nitrogen (2.80 Å) and sidechain oxygen of T161 (2.50 Å), the static water 182 (2.99 Å) 
shown in Fig. 2.2.  W84 acts is involved in P-H…𝜋 interactions as the ring is 3.10 Å from the 
phosphorus atom of hypophosphite.  The residues R210 and D238 are in contact with each other 
capping off  the only side of this ligand binding pocket without direct binding interactions to the 
ligand. 
As seen in the remarkably high resolution 1.03 Å cocrystal structure of HtxB bound to 
phosphite, and similarly to hypophosphite binding, each oxygen atom of the ligand is involved in 
making multiple contacts with HtxB.  The O1 oxygen makes three contacts, the O2 oxygen 
makes two contacts, while the O3 oxygen makes four contacts.  The O1 oxygen atom is bound to 
both the backbone nitrogen (2.84 Å) and sidechain hydroxyl (2.70 Å) of S162, the sidechain 
hydroxyl of Y129 (2.66 Å), and a weaker bond to the sidechain amino group of N160’s  (3.27 
Å).  The O3 oxygen of phosphite also binds similarly to that of hypophosphite’s O2 oxygen.  In 
this case, it also forms contacts with the static water 1 (2.82 Å), along with both the sidechain 
hydroxyl (2.69 Å) and backbone nitrogen (2.98 Å) of T161.  With the addition of a third oxygen 
(O2) atom in phosphite compared to hypophosphite, two new residues come into play when 





η nitrogen 3.11 Å away.  Another P-H…π interaction if formed from the imperfect capping of 
W84 about 3.5 Å away, occluding what would be fourth oxygen in phosphate.   
One would assume, that the oxygens of methylphosphonate, when bound to HtxB, would 
be oriented in an identical way to phosphite’s orientation.  This would put the methyl group 
pointing towards the more hydrophobic side of the pocket towards W84.  To great surprise, as 
seen in the 1.14 Å cocrystal structure of HtxB bound to methylphosphonate, one of the 
methylphosphonate oxygen atoms takes that place.  Luckily, such a high resolution structure was 
solved, as density is slightly less where the methyl group is modeled due to the negative charge 
and resonance of the three oxygen atoms, shown in in Fig, 2.2.  Rather than the methyl group 
taking the place of the hydrogen in phosphite, O05 and O03 of methylphosphonate are in nearly 
the same position of the two oxygens of hypophosphite.  The methyl group is pointed towards 
D238 and R210.  Likely, the polarity of the two residues are masked due to hydrogen bonding.  
With an average distance to the six carbons (CE2, CZ2, CH2, CZ3, CE3, and CD2) of W84 of 
4.19 Å indicating no binding beyond hydrophobic interactions are at play.  While 
methylphosphonate has three oxygen atoms available for forming hydrogen bonds, O04 only 
makes 1 contact, O05 makes three contacts, and O03 makes three contacts.   
The only O04 oxygen atom contact is a hydrogen bond to the side chain nitrogen of N160 
(2.69 Å).  The O05 oxygen atom of methylphosphonate is bound to both the backbone nitrogen 
(2.94 Å) and side chain oxygen of T161 (2.67 Å) and the static water HOH 1 (2.83 Å).  The O03 
oxygen atom is involved in binding to both the sidechain oxygen (2.68 Å) and backbone nitrogen 
(2.78 Å) of S162 along with the sidechain oxygen of Y129 (2.61 Å).  The methyl group instead 
points towards the side chains of R210 and D238, which are now bound to each other rather than 





R210 and D238 provide a structural basis as to why wild type HtxB does not bind to longer 
phosphonate molecules such as 2-aminoethylphosphonate, as they are sterically occluded.  This 
interaction also provides a rational starting point in which to engineer am HtxB variant with an 
enlarged binding pocket capable of binding these larger ligands.  Using Chimera to measure the 
volume of the closed binding cavity present in the methylphosphonate cocrystal structure, as 
result of 129.63 Å3.  Using the same structure as a starting point, in silico an R210L D238A 
double mutant results in the expansion of the binding pocket to 231.77 Å3, a 179% increase of 
volume.  The unique characteristic of HtxB to be able to bind phosphonates, yet occlude binding 
of phosphate may lend mutant variants of this protein to become powerul tools towards purifying 
characterized and novel phosphonate natural products.   
The main hypothesis as to why HtxB is able to bind hypophosphite, phosphite, and 
methylphosphonate, but not phosphate is explained with the presence of W84.  In the case of 
phosphite and hyposphosphite, a P-H…π interaction is at play.  In the case of methyphosphonate, 
this favored interaction is no longer present, presumable lowering affinity to the protein.   
In all cases shown, two positions remain bound by oxygen atoms of the present ligand.  
The first of these two positions is always accompanied by hydrogens bonds to the side chains of 
Y129 and S162, and including N160 for both phosphite and hypophosphite.  The second 
conserved oxygen binding position is comprised of hydrogen bond contacts to both the side 
chain of  T161, and the static water molecule.  Ligand oxygen binding to T161 and S162 







Fig. 2.2. Simulated annealing difference Fourier maps (Fo − Fc) of HtxB complexes contoured to 
2.0σ (green) showing the bound hypophosphite (A), phosphite (B) and methylphosphonate (C) 
and static waters in each binding pocket. The coordinates for the ligand and waters were omitted 
prior to map calculations. The final refined coordinates of the complexes are superimposed with 







Fig. 2.3 Superimposition of HtxB ligands and binding residues showing differences in ligand 
oxygen positioning in relation to residues that form hydrogen bonding contacts to at least one 
ligand. 
 











Fig. 2.4  A superimposition of E. coli PhnD PDB 3P7I (pink) and P. stutzeri HtxB (teal) showing 
the nearly 50 additional residues possessed by PhnD’s C-terminus not found in HtxB.  Overall 






Fig. 2.5  Spatial organization of ligands and binding residues of: (A) HtxB bound to 
methylphosphonate, (B) PhnD bound to 2-aminoethylphosphonate (PDB 3P7I), and (C) an 





In a 3D structural comparison through the DALI35 server, the closest homolog is that of 
E. coli PhnD with an RMSD of 2.2 Å over 254 Cα (300 total cα), a rather striking similarity 
considering the low primary amino acid of 19% identity.  PhnD bound with 2-
aminoethylphosphonate (2-AEP) shows many similarities in its binding site.  PhnD seems to 
have an additional nearly 50 residues at it’s C-terminus compared to HtxB shown in Fig. 2.4.  
Differences in binding pocket residues are shown in Fig 2.5.  The largest difference in binding 
sites involved in phosphoryl binding involved that of Y47, aligned with W84 of HtxB, of PhnD.  
This residue is directly involved in hydrogen binding to a phosphonate oxygen. (H157/F190) 
Another large difference between phosphoryl binding in the two proteins is that H157 of PhnD 
also contributes a hydrogen bond to stabilize the same oxygen atom that Y47 does while the 
aligned HtxB residue, F190, does not.  S127, T128, S129, Y93, and the static water molecule are 
positioned nearly identically compared to that of N160, T161, S162, Y129 the static water in 
HtxB as both sidechain and backbone phosphoryl contacts are conserved.  While the binding 
pocket of PhnD is somewhat expanded compared to that of HtxB, D205 and E177, aligned with 
D238 and R210 in HtxB, are positioned to hydrogen bond with the nitrogen of 2-AEP rather than 
the phosphonate group.  (E177/R210), (D205/D238)  The structural comparison between these 
two proteins, both bound to phosphonates, seem to help confirm the initially confusing 
orientation of methylphosphonate when bound to HtxB, as each carbon or carbon chain are 
positioned similarly. 
Another surprising aspect of HtxB methylphosphonate binding is that none is observed 
via microscale thermophoresis with a 15 minute incubation, even though binding is observed in 
that time scale with hypophosphite.  In this case, binding has been observed after overnight 





methylphosphonate may be a slow tight binder to HtxB, but further experiments such as surface 
plasmon resonance are needed to confirm this hypothesis.  In a study by Hirota et. Al61 it was 
reported that an engineered strain of E. coli, RN1008, with inorganic phosphate and phosphate 
ester transporters knocked out was unable to survive on 1.0 mM methylphosphonate.  This is 
possibly due incompatibility with the transmembrane protein machinery in the HtxBCDE 












Fig. 2.6  Triplicate microscale thermophoresis measurements from an overnight incubation of 







Fig. 2.7 Triplicate hypophosphite microscale thermophoresis measurements after 15 minute 

















When running microscale thermopheresis experiments with inorganic phosphate as a 
ligand, no binding is seen at 15 minute timepoints up to 1 M in concentration.  This observation 
helps to explain why the HtxBCDE cassette is turned on under phosphate starvation64 and is also 
why Hirota et al61 used this transporter to create their engineered E. coli strain with growth 
dependent on hypophosphite or phosphite.  Strangely enough, no binding is observed of 
phosphite to HtxB with microscale thermophoresis in this short timescale as well, however 
RN1008 is able to survive off of phosphite as a sole phosphorus source, and I have observed a 
1.03 Å phosphite bound structure with good ligand density in the same position as other bound 
ligands. 
 Hypophosphite was observed to have rather tight binding to HtxB with a Kd of 49.5 ±5.8 
nM. Binding affinity was determined by microscale thermophoresis shown in Fig. 2.7.  This is to 
be expected of a solute binding protein scavenging for necessary nutrients for cell growth and 
function under duress from lack of a more abundant phosphorus source.   
 
2.4 Concluding Remarks 
 
HtxB is a solute binding protein with specificity towards reduced phosphorus compounds 
while exhibiting no binding of inorganic phosphate. Through structural analysis, the way in 
which these reduced phosphorus compounds are bound by HtxB has been interrogated to be 
through hydrogen bonding and P-H…π interactions.  Unfortunately, there is some ambiguity as 
to how physiologically relevant the binding observed in these crystal structures is.  While there is 
no doubt that hypophosphite binds to HtxB, phosphite and methylphosphonate raise questions.  
While RN1008 is able to survive with phosphite as the sole phosphorus source, it is not able to 





require HtxB to pass through the transmembrane portion of the ABC transporter (HtxCDE).  
This also points towards the inability for methylphosphonate pass through HtxCDE as RN1008 
has the requisite enzymatic machinery to survive with methylphosphonate as a sole phosphorus 
source if it were able to get into the cell.  Further study is needed to address these possibilities by 
testing an HtxB knockout of RN1008 to see how this transporter can work in its absence.  
  This unique binding scope towards reduced phosphorus compounds lends HtxB to be an 
ideal starting point towards the goal of rationally engineering a protein capable for use towards 
bioremediation of toxic phosphonate compounds due to it’s inability to bind the naturally 
common phosphate.  If methylphosphonate proves to be a slow tight binder towards HtxB, this 
would be moreso an ideal starting protein for this task due to a possibly low off rate.  This 
problematic group of molecules includes nerve agents such as sarin, and insecticides such as 
trichloronat which otherwise may stay in the environment, harming whatever effected organisms 

















CHAPTER 3: STRUCTURAL CHARACTERIZATION OF 
A NOVEL ANTIFREEZE POTENTIATING PROTEIN 
FROM P. borchgrevinki 
 
3.1 Introduction 
Freezing avoidance in fishes inhabiting ice-laden polar waters have blood freezing points 
that are well below the freezing point of seawater (-1.9°C).  The low freezing points are 
associated with the presence of blood antifreeze proteins (AFPs)65.  In the Southern Ocean, the 
Antarctic notothenioid Pagothenia (Trematomus) borchgrevinki has a blood freezing point of -
2.7°C the temperature at which ice will propagate in the presence of a seed ice crystal, but the 
melting point of the same size crystal is only -1°C66.  The separation of the melting point and 
freezing point (non-equilibrium freezing point) is often referred to as a thermal hysteresis and is 
the hall mark of AFPs in a variety of organisms in low temperature environments.  In P. 
borchgrevinki, the AFPs are a series of at least 16 different sized antifreeze glycoproteins 
(AFGP) that circulate at levels of 3-4 % W/V67.  They vary in mass from 2.6 to 33 kDa based on 
number of repeat glycotripeptide repeat motifs68.  HPLC quantification of the AFGP in its blood 
serum and freezing/melting point analysis indicate that 4% blood AFGPs account for only 60% 
of the observed thermal hysteresis.  The AFGPs are heat stable and analysis of boiled serum 
confirms that they responsible for slightly more than half of the hysteresis in the native serum69,70  
 A search for an additional blood components with antifreeze properties revealed the 
presence of a heat labile 15 kDa protein with an amino acid sequence similar to the globular head 
of human compliment protein C1q.  Here we report crystal structure of the purified protein which 





large molecular weight AFGPs by two fold but only has an additive effect with the proline 
containing AFGPs smaller than 7 kDa.  
 Antifreeze proteins are widely present throughout eukaryotic and prokaryotic organisms 
such as plants71, fungi72, insects73, fish74, and bacteria.75  Until now, 5 classes of antifreeze 
potentiating proteins have been known to exist in fish. These classes have been termed AFGP, 
for the antifreeze glycoproteins, and AFPs type I-IV based on structural features76.  The 
prevalence of AFPs across domains of life may be attributed to the relative ease of AFP 
evolution from a progenitor non-AFP due to the relative low requirements necessary for an 
active AFP compared to that of an enzyme active site. These requirements are simply a protein 
face with the required surface-surface interactions available via amino acid spacing allowing for 
adhesion onto a nucleated ice crystal.   
In a counterintuitive fashion, hydrogen bonding is not the only important type of 
interaction between AFPs and nucleating ice crystals as shown with threonine to serine and 
threonine to valine mutants of a type I AFP found in winter flounder in which the threonine to 
serine mutant surprisingly lost nearly all of its antifreeze activity, while the threonine to valine 
mutant lost a rather small amount of antifreeze activity77.  This revelation shows that a more 
diverse set of amino acids that first presumed on a protein face can result in antifreeze activity. 
 Understanding AFPs from various sources may have wider applications that their 
endogenous uses by producing organisms.  AFPs have been implicated as food additives and as 
cryopreservatives for tissue samples78,79,80.  Unfortunately, although many beneficial effects have 
been seen using AFPs as cryoprotectants for biological samples, negative effects have been seen 
as well depending on the combination of sample type and AFP used.81  With this knowledge, it is 





combinations, of which this knew class of AFP structure will help by alerting other scientists of a 
new fold for AFPs. A possible, yet hypothetical benefit of this new AFP is related to the 
structural similarity to globular head C1q (ghC1q) proteins, or the gC1q domain, which are often 
membrane proteins found in the brains of chordates.82  The function of many of these C1q 
proteins is unknown, or poorly understood, but in chordates often correlates to brain function and 
immune responses.83,84 
 
3.2 Materials and Methods 
 
 Arthur L. DeVries carried out AFPP was isolation from the blood serum of Pagothenia 
borchgrevinki caught fishing at McMurdo Sound by ammonium sulfate fractionation.  30% 
ammonium sulfate precipitated the heat labile AFPP as well as some larger molecular mass 
proteins.  Following solubilization with a buffer of 25mM NH4HCO3 pH 8.5, the AFPP was 
separated from larger proteins using a 2.5 cm x 135 cm Sephacryl 100 size exclusion column 
(G.E. Healthcare). Using a SuperdexTM 200 10/300 GL analytical size exclusion column, 
standards show AFPP to purify as a trimer as seen in the crystal structure seen in Fig. 3.1 and 
Fig. 3.2.  Acrylamide gel electrophoresis (10-20% gradient gel) of the protein in this fraction 
gave a single coomassie band at approximately 15 kDa and MALDI / MS gave a single mass of 
15.26 kDa.   
Thermal Hysteresis Measurements (Carried out by Arthur L. DeVries) 
Freezing and melting points determined on AFPP solubilized in 25mM NH4HCO3 
showed a freezing melting behavior similar to the AFGPs with the exception that upon freezing 





is in the c-axis direction in the form of spears or spicules.  The antifreeze activity (thermal 
hysteresis) was similar to that of the AFGPs on a weight basis. 
Sequence Determination 
Amino acid analysis carried out by Arthur L. DeVries indicated that the composition was 
unbiased as opposed to some of the other fish AFPs whose composition is 50% or more alanine 
residues such as  the 62% alanine HPLC-6 in winter flounder.77  Sequences obtained by Edman 
degradation of the native protein and of internal tryptic fragments gave sequences used to design 
DNA primers. RT PCR of mRNA from pancreatic tissue gave cDNAs which were extended to 
full length cDNA using RACE.  Since it is not known whether the AFPP is transported from the 
pancreatic tissue to the blood, the purified AFPP was subjected to MS/MS sequencing following 
trypsin digestion.  As well a 43 residue cyanogen bromide peptide was sequenced by Edman 
sequencing.  Using cDNA sequences and protein sequences a derived sequence was obtained that 
agreed with that obtained from the crystal structure with the exception of residues T59, F79, 
A80, Y98, A115, T121, and D127.  Even so, identifications from electron density alone between 
serine and threonine is difficult due to the possibility of combined electron density coming from 
two conformations of a serine side change compared to one of a threonine side chain.  However 
the first 10 N-terminal residues were variable indicating the apparent single gel band and single 
peak eluted from the size exclusion column were most likely composed of similar isoforms.   
 Comparison of the AFPP to database proteins indicated that it had a 34% sequence to the 
globular head of human C1q protein in the blood compliment pathway.  It was even more similar 
to a C1q related protein, cerebellin present in the brain tissue of salmonid fishes with the 





Determination of Polymeric State in Solution 
 Analytical Size exclusion chromatography was carried out with standards from GE, Gel 
Filtration Molecular Weight Markers Kit for Molecular Weights 12,000–200,000 Da Catalog 
Number MWGF200.  Chromatography runs were performed at 1 mL/min using a buffer 
consisting of 300 mM KCl, 20 mM HEPES pH 7.5 and Sephacryl S-200-HR resin.  A single 


















Table 3.1 Crystallographic Refinement Parameters 
  AFPP 
Data collection  
Space Group C 1 2 1 
Wavelength (Å) 0.978720 
Cell: a, b, c (in Å)/ α, γin 82.385, 47.501, 97.472 / 90, 106.292, 90 
Resolution (Å)1 40.75-1.32  (1.367-1.32) 
Total reflections 158,136 (11,652) 
Unique reflections 82,275 (6,537) 
Rmerge (%) 6.69 (30.2) 
I/(I) 8.18 (2.11) 
Completeness (%) 96.74 (77.97) 
Redundancy 1.9 (1.8) 
Refinement  
Resolution (Å) 40.75-1.32 
No. reflections 82269 (6538) 
Rwork / Rfree2 19.35/19.51 






R.m.s deviations  
Bond lengths (Å) 0.016 
Bond angles () 1.91 
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 






3.3 Results and Discussions 
 
 Comparison of the AFPP to database proteins indicated that it had a 34% sequence to the 
globular head of human C1q protein in the blood compliment pathway.  It was even more similar 
to a C1q related protein, cerebellin present in the brain tissue of salmonid fishes with the 
sequence identity being 34%.  A 61% similar protein exists in another cold water fish and fellow 
notothenoid, Dissostichus mawsoni, the Antarctic toothfish , while more divergent homologs are 
also found in salmonid Salmo salar (Atlantic Salmon) at 47%. 
The overall structure of AFPP shows a rotationally symmetrical trimer with putative ice 
binding face solvent exposed on all monomers.  This putative ice binding face is remarkably flat, 
presumably aligning binding residues to match positions of water molecules on a given ice 
crystal face. 
Shown in Fig. 3.3, putative ice binding residues are comprised of a set of serine and 
threonine residues spanning across β-sheets 1 (S14), 3 (T39), 5 (S63), 8 (S100, S102, and S104), 
and 11 (S136).  The average distance between the five side chains on adjacent β-strands across 
all three monomers 4.82 Å is close to the spacing of Hydrogen Bond Acceptors in the prism face 
of cubic ice of 4.52 Å, a spacing seen in some of the insect AFPs as well.85  While this spacing is 
not exact, it is important to remember that the interacting side chains can swing to better 
accommodate an ice face due to rotable bonds.  Coinciding with this first row of regularly spaced 
residues, three serines of β-strand 8 span an average 7.27 Å, aligning well with the 7.38 Å spaced 
water again in the prism face of hexagonal ice.   This could likely represent the ice binding face 






Fig. 3.1 P. borchgrevinki AFPP homo trimer, each monomer colored differently.  A) Top view 








Fig. 3.2  Analytical size exclusion chromatography traces of Alcohol Dehydrogenase from yeast, 
150 kDa (A), Albumin, bovine serum, 66 kDa (B), AFPP trimer, 46 kDa,  (C), and Carbonic 


















Fig. 3.3  Putative ice binding residues span across β-sheets 1 (S14), 3 (T39), 5 (S63), 8 (S100, 






Fig. 3.4 Ordered water molecules between monomers.  D19, K33, and S35 of each monomer 







Fig. 3.5  Simplified view of the ordered water molecule network connected to the side chains of 









 Recently, an antifreeze protein structure was described to have a network of ordered 
water molecules, termed “semi-clathrate.”86  In this study, they describe nearly 400 ordered 
internal water molecules interacting in a repeated pentagonal pattern.  In AFPP, there is a far 
smalled set of ordered water molecules between the three monomers comprised of both 
hexagonal and petagonal spacing shown in Fig. 3.4 and 3.5.  In the crystal structure, the side 
chains of D19, K33, and S35 interact directly with this ordered water molecule network.  The 
importance of this network is not known. 
 
3.4 Concluding Remarks 
  
 While much has been learned about the structure and function of this protein, much is left 
to be done.  Unfortunately, there are always concerns as to how water molecules appear in a 
cryofrozen protein sample and how well that correlates to their positions in a physiological 
context.  More complications are at play as much is not know about this protein in terms that it 
was purified directly from fish serum rather than being heterologously expressed, thus 
constructing site directed mutants.  With these concerns mentioned, a collaboration has been 
planned to test many of the hypotheses laid down by this work through molecular dynamics 
simulations.   
 These simulations should help to provide more evidence as to whether all of the putative 
ice binding residues are indeed necessary for antifreeze potentiation and whether or not their 
spatial configuration does or does not correlate to binding the prism face of cubic ice.  These 
simulations should also help to confirm the importance of the inter-monomer water molecule 
network in the integrity of the trimer.  As AFPP was purified directly from the serum of fish 





generation of large synthetic oligonucleotides, thus this study has not been carried out, but would 
likely prove to be useful in the future for more concrete answers to questions brought forth by 


























CHAPTER 4: INTEROGATION OF AvaR1, A 
BUTENOLIDE RECEPTOR, AND PUTATIVE 
BUTENOLIDE BIOSYNTHETIC PROTEINS 
 
4.1 Introduction 
Since at least 1967, it has been known that small molecules have the ability to drastically 
change the expression profile of streptomycetes through the discovery of A-factor and its ability 
to elicit sporulation and streptomycin in mutant strains otherwise lacking the ability to do so.87  
Since then, much more has been learned about how streptomycetes regulate biosynthetic gene 
clusters involved in secondary metabolism.88  It has been made aware that while A-factor has 
been structurally characterized as a γ-butyrolactone,89 and the receptor of A-factor, ArpA, has 
also been identified.90  It has become apparent that A-factor was the first identified member of a 
larger class of so called microbial hormones produced and effecting dozens of streptomycetes 
insofar as modulating secondary metabolism or regulating sporulation.91  
As ArpA was known to regulate the production of streptomycin, an aminoglycoside 
antibiotic on the World Health Organizations List of Essential Medicine used to treat 
tuberculosis as well as other bacterial infections.92,93  This information along with the rise of 
widespread genomic sequencing which has revealed an abundance of uncharacterized 
biosynthetic gene clusters. In 2001, researches took a statistical approach to try and determine 
just how many antibiotics the genus Streptomyces has the ability produce, and the results were 
astronomical.  While more and more streptomycete genomes are sequences every year, at the 
time, they estimated the biosynthetic potential for 294,300 antimicrobials alone being present in 
the genus.94  According to a 2012 review, 45.2% of all small molecule approved drugs from 





natural products, or derived from natural products.95,96  As there is such a large repertoire of 
uncharacterized natural products in streptomycetes, a concerted effort should come forward to 
characterize this molecules in order to strengthen humanities chemical tool box to fight infection 
and disease. Due to the difficulty of performing genetics in Streptomyces due to their average 
70% GC content in their genome, it would be advantageous to find endogenous regulatory 
systems to hijack for our own gain. 
It turns out that not all ArpA homologs bind γ-butyrolactones, and at least three separate 
classes of receptors, defined by the ligands in which they bind have been identified.  The first of 
these three, the bona fide γ-butyrolactone receptors have already been discussed, and are the 
most well studied. As their name implies, they bind γ-butyrolactones who vary primarily in chain 
length and branched identity. The second class of homologous receptors are the ‘pseudo’ γ-
butyrolactone receptors, which through primary amino acid sequence look rather similar to the 
bona fide receptors, they do not bind γ-butyrolactones, and instead bind and respond to often two 
or more structurally diverse secondary metabolites such as ScbR2 which responds to 
actinorhodin, undecylprodigiosin, and jadomycin B.97,98 
Unlike the bona fide γ-butyrolactones whose biosynthesis has been fleshed out, not much 
is known about the biosynthesis of butenolides such as avenolide.99  What little that is known 
about butenolides has come from gene knockout studies where one of the assumed biosynthetic 
genes aco itself is removed from S. avermitilis,100 or from homologous gene contexts where a 
cyp17 or aco homolog is removed such as orf16* and orf18* in S. fradiae.101  A small number of 
butenolides have been isolated with strikingly similar structures to that of avenolide.102,103,104  
Based on the small number of characterized butenolide structures, and like the varied structures 





variable alkyl tail in terms of oxidation, length, and branched identity. Intriguingly, a few of 
these isolated butenolides have been found to have other activities such as being peroxisome 
proliferator-activated receptor α agonists to exibiting cytotoxicity in cancer cell lines.105,102  
Kitani et. al. had previously identified four Streptomycetes which had a /similar genomic 
context to that of cyp17, avar1, and aco, which led me to believe that it may not be as difficult as 
previously thought to tentatively identify receptors of a given subclass from genomic context due 
to the fact that many γ-butyrolactone receptors are known to be autoregulators along with the 
autoregulation shown for avar1 and tylP.100,101  The high homology between bona fide γ-
butyrolactone receptors like ArpA (40 % sequence identity to AvaR1) and pseudo receptors like 
ScbR2 (40 % sequence identity to AvaR1, 31 % identity to ArpA) and lack of structural 
information revealing ligand and receptor interactions.  Efforts have been made in the past in 
order to discriminate between the receptor classes to varying success. Creating phylogenetic 
trees of a pool of receptors seems to do a decent job of separation, but CprA and CprB still land 
next to each other while in vivo CprA is a positive regulator while CprB is a negative regulator 
for the same gene target despite their 90.7% amino acid identity as shown through gene 
knockouts.106  Another group has used receptor pI as a basis of discriminating receptor 
function107, and while it seemed to serve its purpose for their example, it is a rather crude method 
and should not be trusted as many counter examples exist.  Examples include both acidic and 
basic pseudo receptors such as ScbR2  and JadR2 having an estimated pI of 5.85 and 7.84 
respectively, and positive and negative regulators CprA and CprB having an estimated pI of 9.53 
and 9.77 respectively.  
Through the years, it has become apparent that homologous receptors written about here 





varying scaffold types, leading the belief while not all secondary metabolites in streptomycetes 
are regulated by these receptors, a wide representative breadth of natural product biosynthesis 
may be unlocked by understanding these endogenous regulatory systems. For example, 
antibiotics such as streptomycin are known to be regulated by ArpA and A-factor in 
Streptomyces griseus, the NRPS virginiamycin production regulated by BarA and virginiae 
butanolides from Streptomyces virginiae, 1,5-oxathiocane coelymycin P1 production regulated 
by ScbR and SCB1 in Streptomyces coelicolor, and polyketide anthelminthic avermectin 
regulated by AvaR1 and avenolide in Streptomyces avermitilis.92,107,108,109,100  Another notable 
point about drugs regulated by these systems is that half of the Nobel Prize in Physiology or 
Medicine in 2015 was given for the discovery of avermectin, whose semisynthetic analog 
ivermectin is a widely used broad spectrum antiparasitic drug used to treat river blindness, 
lymphatic filariasis amongst other infections.110,111  Ivermectin is also on the World Health 
Organization’s List of Essential Medicine. 
So far, no other γ-butyrolactone or butenolide receptor structure has been determined, and 
therefore little is known about the structure activity relationship between signaling molecules and 
regulatory receptors in these systems.  With this knowledge, we set out to determine a cocrystal 
structure of AvaR1 and avenolide.  While more is understood about the γ-butyrolactone systems, 
the signaling molecules of those systems are inherently less stable due to their lactone rings in 
comparison to butanolide signaling molecules along, surviving 100 °C for 30 min; acidity of pH 
1 for 30 min; and even basic conditions of pH 11 for 10 min.100  This chemical stability, a 
verified medical relevance, along with a published synthetic scheme for the production of 






4.2 Materials and Methods 
 
Protein purification for crystallographic studies 
Wild type protein was grown in an identical manner for crystallization as with protein 
intended for use in in vitro assays, while preparation of the selenomethionine (SeMet) labeled 
proteins was carried out by the repression of methionine synthesis in defined media.44  Cells 
were pelleted at 3566 x g before resuspension with 500 mM NaCl, 10% glycerol, and 20 mM 
Tris pH 8.0 for lysis. A 6 °C chilled cell homogenizer (Avestin) was utilized for cell lysis using 4 
passes at 7,000 psi. Soluble protein was then separated from the insoluble fraction for 1 h at 
15,400 x g at 4 °C. The protein was loaded onto a HisTrap HP column (GE Healthcare) and 
washed with 50 mL of 1 M NaCl, 20 mM Tris pH 8.0, 30 mM imidazole. A 40 mL gradient 
elution was performed over 20 min starting from the aforementioned wash buffer to 1 M NaCl, 
20 mM Tris pH 8.0, 250 mM imidazole. The MBP tag of SeMet-MBP-AvaR1 was removed over 
12 h via cleavage with thrombin protease with a simultaneous 2 fold dilution of SeMet-MBP-
AvaR1 into dialysis buffer. This dialysis buffer was comprised of 10% glycerol, 5 mM 2-
mercaptoethanol, 300 mM KCl, 20 mM HEPES pH 7.5. Removal of the affinity tag was 
followed by size exclusion chromatography using an ÄKTApurifier with attached Superdex 
HiloadTM 75 16/60column (GE Healthcare) and a flowrate of 1 mL min-1 of running buffer. 
Size exclusion chromatography buffer for all AvaR1 variants consisted of 300 mM KCl, 20 mM 









Table 4.1: Crystallographic refinement parameters 
 SeMet AvaR1 Native AvaR1 
Data collection   
Space Group P1211 P1211 
Wavelength (Å)  0.978720 
Cell: a, b, c (in Å)/ α, γin 
42.03, 78.92, 130.24 / 90, 
93.329, 90 
39.926, 76.015, 126.487 / 90, 
95.616. 90 
Resolution (Å)1 39.27-2.4  (2.486-2.40) 125.88-1.99 (2.061-1.99) 
Total reflections 166,803 201,784 
Unique reflections 33,308 49,468 
Rmerge (%) 13.9 (30.0) 9.0 (45.8) 
I/(I) 7.62 (1.75) 9.11 (2.2) 
Completeness (%) 99.69 (99.94) 95.59 (74.3) 
Redundancy  3.44 (2.9) 
Refinement   
Resolution (Å) 37.99-2.40 41.96-1.99 
No. reflections 33,308  
Rwork / Rfree2 25.0/31.0 23.5/28.6 
Number of atoms   
Protein 6442 6465 
Water 38 59 
B-factors   
Protein 54.65 30.74 
Water 35.82 23.20 
R.m.s deviations   
Bond lengths (Å) 0.015 0.014 
Bond angles () 2.09 1.90 
1Highest resolution shell is shown in parenthesis. 
2R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% 






Table 4.2: Organisms Used in this Study 
 
Crystallization of Native and SeMet AvaR1 Variants 
Dimeric protein was concentrated after size exclusion chromatography with centrifugal 
filters (30 kDa MWCO).  Initial crystallization conditions were determined through 
commercially available sparse matrix crystallization screens using 0.4 µL sitting drops.  Each 
drop contained equal volume of well condition and protein solution.  Optimized crystal 
conditions were determined through hanging drop or sitting drop vapor diffusion methods with 2 
µL drops comprised of equal volumes of protein solution and crystal condition. When stated, 
defined cryoprotective solutions were used prior to the vitrification of protein crystals in 
preparation for data collection.  Cryoprotective solutions were modified well conditions 
supplemented with the noted concentration of cryoprotectant.  All X-ray diffraction data 
collection was at the Life Sciences Collaborative Access Team (Sector 21) at Argonne National 
Laboratory in Lemont, IL. 
The native AvaR1 crystals were obtained through optimization of the initial condition 
(JCSG-plus Tube 1-6) and microseeding to an final well condition of 12% v/v polyethylene 
glycol 1000, 0.1 M Sodium Citrate Tribasic Dihydrate pH 4.2, 0.2 M Li2SO4, 4% v/v tert-butanol 
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at 4 °C with 13.5 mg/mL protein solution.  Hanging drop vapor diffusion was used.  A 
concentration of 20% v/v ethylene glycol was used as a cryoprotectant. 
The SeMet-AvaR1 crystals were obtain through optimization and microseeding of the 
condition (JCSG-plus Tube 2-34) at 4 °C. Sitting drop vapor diffusion was used with protein at a 
concentration of 12 mg/mL and a well condition of 30% v/v polyethylene glycol monomethyl 
ether 2000, and 0.15 M KBr.  No additional cryoprotective was needed. 
 
Determination of the AvaR1 X-ray crystal structures 
Protein was concentrated with a 10 kDa MWCO centrifugal filter after size exclusion 
chromatography.  At least 30 minutes before crystal trays were prepared, protein was incubated 
with the given ligand. Initial crystallization conditions were determined through the use of 
commercially available sparse matrix crystallization screens using 0.4 μL sitting drops 
comprised of an equal volume of ligand incubated protein and well condition.  Crystal condition 
optimizations were carried out using 2 μL drops and the hanging drop vapor diffusion method   
with equal volumes of well condition and protein ligand solution. These cryoprotective solutions 
were prepared as modified mother liquor solutions supplemented with a denoted concentration of 
cryoprotectant. Cryoprotective solutions were used before vitrification of protein crystals prior to 
data collection. All protein crystals used to obtain X-ray diffraction data were obtained at 9 °C, 
and all data were collected at the Life Sciences Collaborative Access Team (Sector-21) Argonne 
National Lab (Lemont, IL). The SeMet-AvaR1 structure was phased with single wavelength 
anomalous diffraction. The heavy atom substructure was determined using HySS as implemented 
in the PHENIX46 suite of programs.  Refinement cycles using REFMAC547 and manual 





resolution avenolide cocrystal structure was solved by Dr. Iti Kapoor using molecular 
replacement with the coordinates of the unbound structure. 
 
Cyp17 Activity Assay 
 Activity towards a panel of free and CoA linked fatty acids, 0.5 µM Cyp17 was incubated 
with 50 µM substrate.  These tests were performed with or without 50 µM NADPH.  Tests were 
carried out at 29 ºC overnight.  
 
Identification of Putative Butenolide Biosynthetic Clusters 
Using the AvaR1 amino acid sequence as a handle, tools from the Enzyme Function 
Initiative (EFI) were used to first create a Sequence Similarity Network (SSN). 
(PMID:25900361) Once a SSN was created, an iterative process was undergone to find an E-
value to ensure characterized receptors of the various GBL families of receptors result with 
mutually exclusive colocalization. The resulting E-value was 10-70. Using this SSN, the data was 
run through the EFI’s Genome Neighborhood Network (GNN) webtool. Network visualization 
was performed in Cytoscape.113  Using Pfams associated with putative avenolide biosynthetic 
genes cyp17, aco, along with the knowledge that this family of receptors often regulates their 
own ligand production, inferences are made as to the class of ligand produced and recognized by 
uncharacterized receptors. Because the EFI webtools are only integrated with the uniprot 
database114, I have also manually scoured through a number of genbank115 BLAST results for 
proper genomic context relative to butenolide production.  These BLAST searches were using 





proper genomic context necessary for butenolide biosynthesis was a TetR_N Pfam receptor 
surrounded by an ACOX (PF01756), Acyl-CoA_dh_1 (PF00441), or Acyl-CoA-dh_2 (PF08028) 
Pfam gene and a gene in the p450 Pfam (PF00067). To my knowledge, all of the sets identified 
in Table 4.4 have the same gene architecture in terms of reading frame direction for the three sets 










Fig. 4.1  Sample Genome Neighborhoods in the AvaR1 containing cluster showing a similar 











Analysis of Structural Conservation Across Putative Butenolide Receptors 
Using the primary amino acid sequences of all putative butenolide receptors in Table 4.4, 
the Clustal Omega multiple sequence alignment web tool was used.116  Once a multiple sequence 
alignment was generated, it was used as an input along with the avenolide bound AvaR1 
structure for Consurf.117  Using Chimera,34 Consurf’s generated conservation scores were 
visualized shown in Fig. 4.8 and 4.10.  
 
Avenolide Synthesis and Dissociation Constant Determination 
Stereochemically pure avenolide was synthesized and isolated by Dr. Iti Kapoor, who 
then performed isothermal titration calorimetry determining the dissociation constant of AvaR1 
and avenolide to be 42.5 ± 2.5 nM. 
 
4.3 Results and Discussions 
  
 Like all other TetR transcriptional repressor family members, AvaR1 is a dimer, each 
monomer comprised of an N-terminal helix-turn-helix containing DNA binding domain and a C-
terminal ligand binding domain.118  In the wholly α-helical AvaR1, the DNA binding domain is 
comprised from α helices 1-4, while the ligand binding domain is comprised of α helices 5-13.  
Dimerization occurs between the two adjacent ligand binding domains as seen in Fig. 4.2.   
When superimposing the whole dimers of AvaR1 bound and not bound to avenolide, no 
obvious domain shifts are present, although information can still be gleamed from this 





the most obvious shift between structures is Q166, swinging into the binding pocket in order to 
make hydrogen bonding contacts to the butenolide ring.  Other shifting residues include most 
notably W128, Q65, and T109.  While in both structures, W128 and Q65 are forming hydrogen 
bonds between residues, when avenolide is bound to AvaR1, Q65 and T109 make an additional 
contact.  This additional contact seems to shift the entire loop between helices 4 and 5.  This shift 
is more noticeable when dimers are superimposed based only on a single DNA binding domain 
shown in Fig. 4.3. 
In this superimposition, it becomes apparent that the new contacts between W128, Q65, 
and T109 are likely the necessary residues that couple ligand binding to the end conformational 
shift leading to dissociation of AvaR1 from the DNA duplex.  When drawing a line through helix 
1 of adjacent monomers, an overall shift of about 20º.  Unfortunately, no DNA bound structure 
has been solved of AvaR1, so this comparison is the best picture currently available of 








Fig. 4.2  AvaR1 dimer with the DNA binding domain of chain A in green and the ligand binding 






Fig. 4.3 AvaR1 bound to (orange) and not bound (blue) to avenolide when superimposing the 
DNA binding domains of a single monomer reveal a nearly 20º shift in the adjacent monomer’s 
DNA binding domain. 






















 While nearly nothing is currently known about the specifics of butenolide biosynthesis, 
with known important enzymes identified (Cyp17119, Aco120, AdhA5121, and their homologs) a 
rough picture can be drawn out in Fig. 4.5.  It is not known what starting material is used 
endogenously, but given the end structure of avenolide, and the few other known butenolides, it 
would make sense to start with some sort of fatty acid based substrate.  The order of action of 
Cyp17, Aco, and AdhA5 among possible unidentified enzymes is also not known, further adding 
density to the fog surrounding the problem.  For avenolide specifically, an anteiso-C13 acid 
based substrate would not necessarily require an unknown enzyme for final avenolide 
biosynthesis.  Such anteiso fatty acids are known to be produced by Streptomyces.122 
Knowing the similarity of these enzymes to homologs with known functions, Cyp17 can 
be presumed to modify the alkyl chain of a starting molecule, opening questions as to if Cyp17 is 
a mono- or dioxygenase to install the C8 and C9 oxygens in the form of hydroxyl groups.  
Presumably, AdhA5, with similarities to other alcohol dehydrogenases would then be left to 
convert the C8 hydroxyl to the keto form.  With these modifications accounted for, ring 







Fig. 4.5 Putative avenolide biosynthetic scheme, where R represents possible starting materials 






Preliminary assays have been carried out as to identify the roles of putative avenolide 
biosynthetic enzymes.  Towards this goal Cyp17 was tested against a small panel of free or CoA 
linked fatty acid substrates in Table 4.3.  Only one member of the panel exhibited any mass 
change when incubated with Cyp17, 3-hydroxydecanoic acid indicating the addition of two 
oxygen atoms shown in Fig 4.6.  Unfortunately, the positions of these additional atoms is not 
known, but the addition of these two oxygen atoms fits well with the putative biosynthetic 
scheme.  While it is not immediately obvious as to why this is the case, with added confusion 
due to an unknown starting molecule in avenolide biosynthesis.   
 
Table 4.3: Cyp17 Activity Against Fatty Acid Based Substrates 
Substrate  Mass Shift 
Hexanoyl-CoA 0 
Octanoic acid 0 
3-Hydroxyoctanoic acid +32 Da 
Decanoic acid 0 
3-Hydroxydecanoic acid 0 
Dodecanoic acid 0 








Fig. 4.6 The no enzyme negative control of Cyp17 assay condition with 3-hydroxyoctanoic acid 
(159.1 m/z) (A), and Cyp17 activity assay showing a peak of 191.07 m/z, 32 Da more than 3-






In order to determine whether butenolide signaling is widespread in streptomycetes, a 
bioinformatic search was performed targeting homologs of the putative avenolide biosynthetic 
genes.  A total of 63 putative biosynthetic protein and receptor sets have been identified.  As 
more streptomycete genomes become sequenced, helped with the lowering cost and more 
widespread availability of such a technique, only more butenolide biosynthesis-receptor sets will 
be identified.  To reiterate the point that this may be the tip of the ice berg of identifying 
butenolide signaling related proteins, the UniProt database, that being the database of which SSN 
and GNN data is pulled, is currently growing at a rate of 2.5% a month, resulting in a doubling 
time of 2.5 years.123 
Using available information in literature as a number of identified butanolide 
(ArpA/Uniprot Q9ZN78, ScbR/Uniprot O86852), and pseudo receptors (ScbR2/Uniprot Q93S03 
JadR2/Uniprot Q56153) have been characterized as well as AvaR1 as a sequence handle for the 
butenolide receptors, receptor classes segregate into separate clusters seen in Fig. 4.7.  
When applying conservation scores to the avenolide bound AvaR1 structure, it appears 
that most of the conserved residues are involved in intramolecular binding between helices 
seemingly important for overall domain structure as mutations abrogating the function of the 
ligand binding domain can only have negative effects when signal is needed.  When looking into 
structurally superimposed residues of AvaR1 to the DNA bound CprB structure,124 all of the 
residues are highly conserved amongst putative butenolide receptors, with S34 having the lowest 





When looking into the ligand binding cleft between helices 5-8 shown in Fig. 4.10, that 
there is more variability in residues surrounding the alkyl tail of avenolide rather than the 
butenolide ring itself.  If butenolides, as a ligand class, are indeed similar in variability to the 
butanolides, this makes sense, as the ring is held constant, while decorations and length of the 












Table 4.4: Putative Butenolide Receptor, Biosynthetic Gene Sets 
Receptor  













A0A0N1IYE7 ADK59_29015 A0A0N0UPM2 ADK59_RS28945 A0A0M9CL62 ADK59_RS28935 sp. XY332 AvaR1 SSN 
A0A0M9YCZ0 ADK54_RS22575 A0A0N0SFG3 ADK54_RS22580 A0A0N0SFG5 ADK54_RS22570 sp. WM6378 AvaR1 SSN 
Q8VVP1 SPRI_RS01555 A0A0M4D0C2 SPRI_RS01560 D9UBX1 SPRI_RS01550 pristinaespiralis AvaR1 SSN 
Q8VVP1 SPRI_RS34865/spbR A0A0M4DZ78 SPRI_RS34860 D6X7G5 SPRI_RS34870 pristinaespiralis AvaR1 SSN 
A0A1B1B185 AVL59_26260 A0A1B1BD80 AVL59_RS26265 A0A1B1B170 AVL59_RS26255 
griseochromogenes strain 
ATCC 14511 AvaR1 SSN 
A0A0Q9AR33 ASE41_15570/scaR A0A0Q9AQI4 ASE41_RS08690 A0A0Q9B2T8 ASE41_RS08700 sp. Root264 AvaR1 SSN 
S5UWW2 B446_03460 S5VGF9 B446_RS03395 S5UKW3 B446_RS03385 
collinus (strain DSM 40733 / 
Tu 365) AvaR1 SSN 
A0A0K8PJS6 SAZU_2710 A0A0K8PKP0 AOQ53_RS12925 A0A0K8PJB0 AOQ53_RS12915 azureus strain ATCC 14921 AvaR1 SSN 
Q9ZHP8/Q9XCC7  tylQ Q9XCC8 orf18 Q9XCC6 orf16 fradiae AvaR1 SSN 
A0A0C5FX10 TU94_00975 None TU94_RS00980 A0A0C5FRN7 TU94_RS00965 
cyaneogriseus subsp. 
noncyanogenus AvaR1 SSN 
A0A0W7X8Q7 AT728_21175 A0A0W7X7X8 AT728_RS06415 A0A0W7X879 AT728_RS06425 silvensis AvaR1 SSN 
D6AAS8 SSFG_07848 D6AAS9 SSFG_07849 D6AAS7 SSFG_07847 ghanaensis ATCC 14672 AvaR1 SSN 
A0A117S2T9 AQJ91_00095 A0A101V605 AQJ91_RS00090 A0A101V680 AQJ91_RS00100 sp. RV15 AvaR1 SSN 
A0A089Z5H9 SGLAU_25540 A0A089XIM7 SGLAU_RS25200 A0A089XGJ6 SGLAU_RS25210 glaucescens AvaR1 SSN 
A0A101NM43 AQI88_17505 A0A101NM57 AQI88_RS17500 A0A117PW75 AQI88_RS17510 cellostaticus AvaR1 SSN 
Q82H41 avaR1 A0A1T1CV76 aco/SM007_06205 Q82H42 cyp17 avermitilis AvaR1 SSN 
Q9XCC7 BEN35_RS25960 Q9XCC8 BEN35_RS25965 A0A081ECC6 BEN35_RS25955 fradiae strain Olg4R AvaR1 SSN 
D6AAS8 STRVIR_RS0136700 D6AAS9 STRVIR_RS0136690 D6AAS7 STRVIR_RS0136705 viridosporus T7A AvaR1 SSN 
F3NSD0 SGM_6044 F3NSD1 SGM_6045 F3NSC9 SGM_6043 griseoaurantiacus M045 AvaR1 SSN 
A0A101SRY8 AQJ66_RS29075 A0A117R9W4 AQJ66_29065 A0A117R9X0 AQJ66_RS29080 bungoensis aco SSN 
A0A1S2QKV5 BIV23_RS09990 A0A1S2QKY9 BIV23_RS09995 A0A1S2QIV0 BIV23_RS09985 sp. MUSC 1 aco SSN 
none OP17_RS26145 None OP17_RS26140 none OP17_RS26150 
aureofaciens strain NRRL B-
1286 
from ncbi blast 
of aco 
none AOK23_RS06340 None AOK23_RS06335 none AOK23_RS06345 torulosus strain NRRL B-3889 
from ncbi blast 
of aco 
none AOK12_RS18690 None AOK12_RS18695 none AOK12_RS18685 
kanamyceticus strain NRRL B-
2535 
from ncbi blast 
of aco 
none AOK14_RS28840 None AOK14_RS28845 none AOK14_RS28835 
neyagawaensis strain NRRL B-
3092 
from ncbi blast 
of aco 
none JHAT_RS31450 
92% ID to 
azureus JHAT_RS31455 none JHAT_RS31445 sp. JHA26 







Table 4.4 (cont.) 




from ncbi blast of 
aco 
none IH57_RS0113175 None IH57_RS0113170 none IH57_RS0113180 sp. NRRL F-5053 
from ncbi blast of 
aco 




from ncbi blast of 
aco 
none AWZ10_RS30605 None AWZ10_RS30600 none AWZ10_RS30610 
europaeiscabiei 
strain 96-14  
from ncbi blast of 
aco 
A0A1Q5L629 AMK31_RS05975 None AMK31_RS05980 A0A1Q5L6K6 AMK31_RS05970 sp. TSRI0107 
from ncbi blast of 
aco 
none OQI_RS18015 None OQI_RS18020 A0A1Y2PU37 OQI_RS18010 pharetrae CZA14 
from ncbi blast of 
aco 
none AOK15_RS33540 None AOK15_RS33545 none AOK15_RS33535 
ossamyceticus strain 
NRRL B-3822 
from ncbi blast of 
aco 
none AOK17_RS00790 None AOK17_RS00795 none AOK17_RS00785 
phaeochromogenes 
strain NRRL B-1248 
from ncbi blast of 
cyp17 
none B079_RS0125750 None B079_RS0125745 none B079_RS0125755 sp. LaPpAH-108 
from ncbi blast of 
cyp17 
A0A1Q5KW18 AMK33_RS39295/AMK33_38290 A0A1Q5KW30 AMK33_RS39290 A0A1Q5KVZ5 AMK33_RS39300 sp. CB02400 
from ncbi blast of 
cyp17 
none ASC56_RS07050 None ASC56_RS07055 none ASC56_RS07045 sp. TP-A0356 
from ncbi blast of 
cyp17 
A0A233RWJ5 BEK98_43205 A0A233RWK1 BEK98_43200 A0A233RWI3 BEK98_RS44190 diastatochromogenes 
Jan2018 AvaR1 
SSN/GNN 















































Table 4.4 (cont.) 










A0A2G6ZU20 BX282_0700 A0A2G6ZTU2 BX282_0701 A0A2G6ZTS4 BX282_0699 
sp. 1121.2 
Ga0151191_11 4/6/18 SSN AvaR1 
A0A286G6J2 SAMN06272765_6800 A0A286G6P6 SAMN06272765_6799 A0A286G6S2 SAMN06272765_6801 
sp. Ag109_G2-
15 4/6/18 SSN AvaR1 
A0A269TXR8 CJD44_11095 A0A269TZZ6 CJD44_11100 A0A269TXT9 CJD44_11090 sp. alain-838 
4/12/18 EMBL 
BLASTw/AvaR1 
none C3488_RS02995 None C3488_RS03000 none C3488_RS02990 sp. Ru72 
4/17/18 Cyp17 
BLAST genbank 
none C6Y14_RS06395 None C6Y14_06390 none C6Y14_RS06400 sp. A217 
4/17/18 Cyp17 
BLAST 
none IF73_RS0131080 None IF73_RS0131075 none IF73_RS0131085 NRRL F-5727 
4/17/18 Cyp17 
BLAST 
none C6N75_RS16880 None C6N75_RS16885 none C6N75_RS16875 sp. ST5x 
4/17/18 Cyp17 
BLAST 
none VO63_07870 None VO63_07865 none VO63_07875 showdoensis 
4/17/18 Cyp17 
BLAST 
none IF54_RS0133395 None IF54_RS0133390 none IF54_RS0133400 NRRL B-3229 
4/17/18 Cyp17 
BLAST 
none EW58_RS46355 None EW58_RS46360 none EW58_RS46350 mirabilis 
4/17/18 Cyp17 
BLAST 
none BG482_RS07255 None BG482_RS07260 none BG482_RS07250 sp. LUP30 
4/17/18 Cyp17 
BLAST 
none CLW08_RS34500 None CLW08_RS34495 none CLW08_RS34505 sp. 69 
4/17/18 Cyp17 
BLAST 
none STEPF7_RS00065 None STEPF7_RS00060 none STEPF7_RS00070 sp. F-7 
4/17/18 Cyp17 
BLAST 
none CW362_RS40740 None CW362_RS40735 none CW362_RS40745 sp. A249 
4/17/18 Cyp17 
BLAST 
none C6376_26350 None C6376_26345 none C6376_26355 sp. P3 
4/17/18 Cyp17 
BLAST 
none ASC56_RS07050 None ASC56_RS39460 none ASC56_RS07045 sp. TP-A0356 
4/19/18 AvaR1 
BLAST 











Fig. 4.8 Avenolide bound consurf model applied onto chain A, avenolide in red.  Coservation 
scores determined using the aligned amino acid sequences of the 63 putative butenolide receptors 









Table 4.5: Conservation of Putative DNA Binding Residues Across Butenolide Receptors 

















Fig. 4.9 Superimposition of DNA binding domains of CprB (PDB 4PXI) in tan and AvaR1 in 
orange.  Residues identified to bind to DNA in CprB and structurally overlapping side chains are 














Table 4.6: Conservation of Avenolide Binding Residues Across Putative Butenolide 
Receptors 
AvaR1 Residue  Conservation (%) Proposed Function 
Q65 100 Couples ligand binding  
T109 100 to domain shift 
W128 100  
T163 98 Ring binding 
Q166 100  
L89 95 Alkyl tail binding 
V106 50  
T132 24  
V159 82  
F162 97  
Y186 55  
 
 
4.4 Concluding Remarks 
 
 Through this work, the first crystal structure of a butenolide receptor has been unveiled, 
and information of the receptor class as a whole has come to light.  This work lays the 
foundation for the relatively simple and rational identification of putative butenolide receptors 
though the use of sequence similarity networks and genome neighborhood networks.  Through 
this identification, new candidates for study may be quickly identified.  Through the structural 
comparison of AvaR1 bound to and not bound to avenolide, residues important for binding and 
conformational changes have been identified for verification of later studies.  Combining this 
structural information with the dozens of putative butenolide receptors identified, weight is 





in butenolide structure as a ligand class.  Another contribution from this work is the start of 
interrogating function of putative butenolide biosynthetic genes.  While much more is to do done 
across these fronts, and with every new Streptomyces genome sequenced, new receptors may 
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